The present inventors have discovered that alpha-Aminoadipate Reductase and Homocitrinate Synthase are each essential for fungal pathogenicity. Specifically, the inhibition of alpha-Aminoadipate Reductase or Homocitrinate Synthase gene expression in fungi results in no signs of successful infection or lesions. Thus, alpha-Aminoadipate Reductase or Homocitrinate Synthase can be used as a target for the identification of antibiotics, preferably antifungals. Accordingly, the present invention provides methods for the identification of compounds that inhibit alpha-Aminoadipate Reductase or Homocitrinate Synthase expression or activity. The methods of the invention are useful for the identification of antibiotics, preferably antifungals.
Title: PROCÉDÉS D’IDENTIFICATION D’INHIBITEURS D’ALPHA-AMINOACIDIPATE RÉDUCTASE ET D’HOMOCITRATE SYNTHASE EN TANT QU’ANTIBIOTIQUES

Title: METHODS FOR THE IDENTIFICATION OF INHIBITORS OF ALPHA-AMINOACIDIPATE RÉDUCTASE AND HOMOCITRATE SYNTHASE AS ANTIBIOTICS

Abrégé/Abstract:
The present inventors have discovered that α-Aminoadipate Reductase and Homocitrinate Synthase are each essential for fungal pathogenicity. Specifically, the inhibition of α-Aminoadipate Reductase or Homocitrinate Synthase gene expression in fungi results in no signs of successful infection or lesions. Thus, α-Aminoadipate Reductase or Homocitrinate Synthase can be used as a target for the identification of antibiotics, preferably antifungals. Accordingly, the present invention provides methods for the identification of compounds that inhibit α-Aminoadipate Reductase or Homocitrinate Synthase expression or activity. The methods of the invention are useful for the identification of antibiotics, preferably antifungals.
Title: METHODS FOR THE IDENTIFICATION OF INHIBITORS OF ALPHA-AMINOADIPATE REDUCTASE AND HOMOCITRATE SYNTHASE AS ANTIBIOTICS

L-2-Aminoadipate + NADPH + ATP

α-Aminoadipate Reductase + Mg^{2+}

L-2-Aminoadipate 6-semialdehyde + NADP+ + AMP + pyrophosphate + H2O

Abstract: The present inventors have discovered that α-Aminoadipate Reductase and Homocitrate Synthase are each essential for fungal pathogenicity. Specifically, the inhibition of α-Aminoadipate Reductase or Homocitrate Synthase gene expression in fungi results in no signs of successful infection or lesions. Thus, α-Aminoadipate Reductase or Homocitrate Synthase can be used as a target for the identification of antibiotics, preferably antifungals. Accordingly, the present invention provides methods for the identification of compounds that inhibit α-Aminoadipate Reductase or Homocitrate Synthase expression or activity. The methods of the invention are useful for the identification of antibiotics, preferably antifungals.
Published: without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.
METHODS FOR THE IDENTIFICATION OF INHIBITORS OF
ALPHA-AMINOADIPATE REDUCTASE AND HOMOCITRATE SYNTHASE AS
ANTIBIOTICS

RELATED APPLICATIONS

This application claims the benefit of U.S. Patent Application No. 10/011,146,
the contents of which are incorporated by reference.

FIELD OF THE INVENTION

The invention relates generally to methods for the identification of antibiotics,
preferably antifungals that affect the biosynthesis of lysine.

BACKGROUND OF THE INVENTION

Filamentous fungi are the causal agents responsible for many serious
pathogenic infections of plants and animals. Since fungi are eukaryotes, and thus
more similar to their host organisms than, for example bacteria, the treatment of
infections by fungi poses special risks and challenges not encountered with other
types of infections. One such fungus is Magnaporthe grisea, the fungus that causes
rice blast disease. It is an organism that poses a significant threat to food supplies
worldwide. Other examples of plant pathogens of economic importance include the
pathogens in the genera Agaricus, Alternaria, Anisogramma, Anthracodea, Antrodia,
Apiognomonia, Apiosporina, Armillaria, Ascochyta, Aspergillus, Bipolaris,
Bjerkandera, Botryosphaeria, Botrytis, Ceratobasidium, Ceratocystis, Cercospora, Cercosporidium, Cerotelium, Cerrena, Chondrostereum, Chryphonectria, Chrysomyxa, Cladosporium, Claviceps, Cochliobolus, Coleosporium, Colletotrichum, Colletotrichum, Corticium, Corynespora, Cronartium, Cryptonectria, Cryptosphaeria, Cyathus, Cymadothea, Cytospora, Daedaleopsis, Diaporthe, Didymella, Diplocarpon, Diploodia, Dischahinea, Discula, Dothistroma, Drechslera, Echinodontium, Elsinoe, Endocronartium, Endothia, Entyloma, Epichloe, Erysiphe, Exobasidium, Exserohilum, Fomes, Fomitopsis, Fusarium, Gaemanonnymex, Ganoderma, Gibberella, Gloecercospora, Gloeophyllum, Gloeosporus, Glomerella, Gnomoniella, Guignardia, Gymnosporangium, Helminthosporium, Herpotrichia, Heterobasidion, Hirschioporus, Hypodermella, Inonotus, Irpex, Kabatiella, Kabatina, Laetiporus, Laetisaria, Lasiodiplodia, Laxitextum, Leptographium, Leptosphaeria, Leptosphaerulina, Leucosporia, Linospora, Lophodermella, Lophodermium, Macrophomina, Magnaporthe, Marssonina, Melampsora, Melampsorella, Meria, Microdochium, Microsphaera, Monolinia, Monochaeta, Morchella, Mycosphaerella, Myrothecium, Nectria, Nigrospora, Ophiosteraella, Ophiostoma, Penicillium, Perenniporia, Peridermium, Pestalotia, Phaeocryptopus, Phaeolus, Phakopsora, Phellinus, Phialophora, Phoma, Phomopsis, Phragmidium, Phyllachora, Phyllosticta, Phymatotrichopsis, Pleospora, Podosphaera, Pseudopeziza, Pseudoseptoria, Puccinia, Pucciniastrum, Pyricularia, Rhabdocline, Rhizoctonia, Rhizopus, Rhizosphaera, Rhyynchosporium, Rhytisma, Schizophyllum, Schizpora, Scirrhia, Sclerotinia, Sclerotium, Scytinostroma, Septoria, Setosphaera, Siroccocus, Spaerotheca, Sphaeropsis, Sphaerotheca, Sporisorium, Stagonospora, Stemphyllium, Stenocarpella, Stereum, Taphrina, Thielaviopsis, Tilletia, Trametes, Tranzschelia, Trichoderma, Tubakia, Typhula, Uncinula, Urocystis, Uromyces, Ustilago, Valsa, Venturia, Verticillium, Xylaria, and others. Related organisms in the classification, oomycetes, that include the genera Albugo, Aphanomyces, Bremia, Peronospora, Phytophthora, Plasmodiophora, Plasmopara, Pseudoperonospora, Pythium, Sclerophthora, and others are also significant plant pathogens and are sometimes classified along with the true fungi. Human diseases that are caused by filamentous fungi include life-threatening lung and disseminated diseases, often a result of infections by Aspergillus fumigatus. Other fungal diseases in animals are caused by fungi in the genera, Fusarium, Blastomyces, Microsporum, Trichophyton,
*Epidermophyton, Candida, Histoplasma, Pneumocystis, Cryptococcus,* other *Aspergilli,* and others. The control of fungal diseases in plants and animals is usually mediated by chemicals that inhibit the growth, proliferation, and/or pathogenicity of the fungal organisms. To date, there are less than twenty known modes-of-action for plant protection fungicides and human antifungal compounds.

A pathogenic organism has been defined as an organism that causes, or is capable of causing disease. Pathogenic organisms propagate on or in tissues and may obtain nutrients and other essential materials from their hosts. A substantial amount of work concerning filamentous fungal pathogens has been performed with the human pathogen, *Aspergillus fumigatus.* Shibuya et al. (Shibuya, K., M. Takaoka, et al. (1999) Microb Pathog 27: 123 - 31 (PMID: 10455003)) have shown that the deletion of either of two suspected pathogenicity related genes encoding an alkaline protease or a hydrophobin (rodlet) respectively, did not reduce mortality of mice infected with these mutant strains. Smith et al. (Smith, J. M., C. M. Tang, et al. (1994) Infect Immun 62: 5247 - 54 (PMID: 7960101)) showed similar results with alkaline protease and the ribotoxin restrictocin; *Aspergillus fumigatus* strains mutated for either of these genes were fully pathogenic to mice. Reichard et al. (Reichard, U., M. Monod, et al. (1997) J Med Vet Mycol 35: 189 - 96 (PMID: 9229335)) showed that deletion of the suspected pathogenicity gene encoding, aspergillopepsin (PEP) in *Aspergillus fumigatus,* had no effect on mortality in a guinea pig model system, and Aufauvre-Brown et al (Aufauvre-Brown, A., E. Mellado, et al. (1997) Fungal Genet Biol 21: 141 – 52 (PMID: 9073488)) showed no effects of a chitin synthase mutation on pathogenicity. However, not all experiments produced negative results. Ergosterol is an important membrane component found in fungal organisms. Pathogenic fungi that lack key enzymes in this biochemical pathway might be expected to be non-pathogenic since neither the plant nor animal hosts contain this particular sterol. Many antifungal compounds that affect this biochemical pathway have been described (Onishi, J. C. and A. A. Patchett (1990a, b, c, d, and e) United States Patents 4,920,109; 4,920,111; 4,920,112; 4,920,113; and 4,921,844, Merck & Co. Inc. (Rahway NJ)) and (Hewitt, H. G. (1998) Fungicides in Crop Protection Cambridge, University Press). D’Enfert et al. (D’Enfert, C., M. Diaquin, et al. (1996) Infect Immun 64: 4401 - 5 (PMID: 8926121)) showed that an *Aspergillus fumigatus* strain mutated in an orotidine 5'-phosphate decarboxylase gene was entirely non-pathogenic in mice, and Brown et al. (Brown, J. S., A. Aufauvre-Brown, et al. (2000) Mol
Microbiol 36: 1371-80 (PMID: 10931287)) observed a non-pathogenic result when genes involved in the synthesis of para-aminobenzoic acid were mutated. Some specific target genes have been described as having utility for the screening of inhibitors of plant pathogenic fungi. Bacot et al. (Bacot, K. O., D. B. Jordan, et al. (2000) United States Patent 6,074,830, E. I. du Pont de Nemours & Company (Wilmington DE)) describe the use of 3,4-dihydroxy-2-butanone 4-phosphate synthase, and Davis et al. (Davis, G. E., G. D. Gustafson, et al. (1999) United States Patent 5,976,848, Dow AgroSciences LLC (Indianapolis IN)) describe the use of dihydroorotate dehydrogenase for potential screening purposes.

There are also a number of papers that report less clear results, showing neither full pathogenicity nor non-pathogenicity of mutants. Hensel et al. (Hensel, M., H. N. Arst, Jr., et al. (1998) Mol Gen Genet 258: 553 - 7 (PMID: 9669338)) showed only moderate effects of the deletion of the areA transcriptional activator on the pathogenicity of Aspergillus fumigatus. Tang et al. (Tang, C. M., J. M. Smith, et al. (1994) Infect Immun 62: 5255 - 60 (PMID: 7960102)) using the related fungus, Aspergillus nidulans, observed that a mutation in para-aminobenzoic acid synthesis prevented mortality in mice, while a mutation in lysine biosynthesis had no significant effect on the mortality of the infected mice.

Therefore, it is not currently possible to determine which specific growth materials may be readily obtained by a pathogen from its host, and which materials may not. Surprisingly, especially in light of the results showing that a lysine biosynthesis mutation in the filamentous fungus, Aspergillus nidulans, had no significant effect on the pathogenicity in a mouse model system (Tang, C. M., J. M. Smith, et al. (1994) Infect Immun 62: 5255 - 60 (PMID: 7960102)), we have found that Magnaporthe grisea that cannot synthesize their own lysine are entirely non-pathogenic on their host organism. To date there do not appear to be any publications demonstrating an anti-pathogenic effect of the knock-out, over-expression, antisense expression, or inhibition of the genes or gene products involved in lysine biosynthesis in filamentous fungi. Thus, it has not been shown that the de novo biosynthesis of lysine is essential for fungal pathogenicity. Our work with homocitrate synthase in the lysine pathway shows that the disruption of lysine biosynthesis as the result of a disruption of the gene encoding the enzyme activity, homocitrate synthase, also results in a non-pathogenic phenotype for M. grisea. Thus, it would be desirable to determine the utility of the enzymes involved in lysine biosynthesis for evaluating
antibiotic compounds, especially fungicides. If a fungal biochemical pathway or specific gene product in that pathway is shown to be required for fungal pathogenicity, various formats of in vitro and in vivo screening assays may be put in place to discover classes of chemical compounds that react with the validated target gene, gene product, or biochemical pathway, and are thus candidates for antifungal, biocide, and biostatic materials.

SUMMARY OF THE INVENTION

Surprisingly, the present inventors have discovered that in vivo disruption of the gene encoding α-Aminoadipate Reductase and, separately, in vivo disruption of the gene encoding Homocitrate Synthase in Magnaporthe grisea each prevents or inhibits the pathogenicity of the fungus. Both of these enzymes are involved in the biosynthesis of lysine. Thus, the present inventors have discovered that α-

Aminoadipate Reductase and Homocitrate Synthase are each essential for normal rice blast pathogenicity, and can be used as a target for the identification of antibiotics, preferably fungicides. Accordingly, the present invention provides methods for the identification of compounds that inhibit the expression or activity of α-Aminoadipate Reductase or, separately, of Homocitrate Synthase. The methods of the invention are useful for the identification of antibiotics, preferably fungicides.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the reaction performed by α-Aminoadipate Reductase (AAR1) reaction. The Substrates/Products are L-2-Aminoadipate + NADPH + ATP and the Products/Substrates are L-2-Aminoadipate 6-semialdehyde + NADP+ + AMP + pyrophosphate + H₂O. The function of the α-Aminoadipate Reductase enzyme is the interconversion of L-2-Aminoadipate, NADPH, and ATP to L-2-Aminoadipate 6-semialdehyde, NADP+, AMP, pyrophosphate, and H₂O. This reaction is part of the lysine biosynthesis pathway.

Figure 2 shows a digital image showing the effect of AAR1 gene disruption on Magnaporthe grisea pathogenicity using whole plant infection assays. Rice variety
CO39 was inoculated with wild-type and the transposon insertion strains, KO1-1 and KO1-11. Leaf segments were imaged at five days post-inoculation.

Figure 3. Verification of Gene Function by Analysis of Nutritional Requirements. Wild-type and transposon insertion strains, KO1-1 and KO1-11, were grown in (A) minimal media and (B) minimal media with the addition of L-lysine, respectively. The x-axis shows time in days and the y-axis shows turbidity measured at 490 nanometers and 750 nanometers. The symbols represent wildtype (—○—), transposon strain KO1-1 (—■—), and transposon strain KO1-11 (—▲—).

Figure 4 shows the reaction performed by the homocitrate synthase (HCS1) reaction. The Substrates/Products are Acetyl CoA + H₂O + 2-oxoglutarate and the Products/Substrates are 2-hydroxybutane-1,2,4-tricarboxylate + CoA. The function of the homocitrate synthase enzyme is the interconversion of Acetyl CoA, 2-oxoglutarate, and H₂O to 2-hydroxybutane-1,2,4-tricarboxylate and CoA. This reaction is part of the lysine biosynthesis pathway.

Figure 5 shows a digital image showing the effect of HCS1 gene disruption on Magnaporthe grisea pathogenicity using whole plant infection assays. Rice variety CO39 was inoculated with wild-type and the transposon insertion strains, KO1-1 and KO1-2. Leaf segments were imaged at five days post-inoculation.

Figure 6. Verification of Gene Function by Analysis of Nutritional Requirements. Wild-type and transposon insertion strains, KO1-1 and KO1-2, were grown in (A) minimal media and (B) minimal media with the addition of L-lysine, respectively. The x-axis shows time in days and the y-axis shows turbidity measured at 490 nanometers and 750 nanometers. The symbols represent wildtype (—○—), transposon strain KO1-1 (—■—), and transposon strain KO1-2 (—▲—).

**DETAILED DESCRIPTION OF THE INVENTION**

Unless otherwise indicated, the following terms are intended to have the following meanings in interpreting the present invention.

The term "active against" in the context of compounds, agents, or compositions having antibiotic activity indicates that the compound exerts an effect on a particular target or targets which is deleterious to the *in vitro* and/or *in vivo*
growth of an organism having that target or targets. In particular, a compound active against a gene exerts an action on a target which affects an expression product of that gene. This does not necessarily mean that the compound acts directly on the expression product of the gene, but instead indicates that the compound affects the expression product in a deleterious manner. Thus, the direct target of the compound may be, for example, at an upstream component which reduces transcription from the gene, resulting in a lower level of expression. Likewise, the compound may affect the level of translation of a polypeptide expression product, or may act on a downstream component of a biochemical pathway in which the expression product of the gene has a major biological role. Consequently, such a compound can be said to be active against the gene, against the gene product, or against the related component either upstream or downstream of that gene or expression product. While the term "active against" encompasses a broad range of potential activities, it also implies some degree of specificity of target. Therefore, for example, a general protease is not "active against" a particular gene which produces a polypeptide product. In contrast, a compound which inhibits a particular enzyme is active against that enzyme and against the gene which codes for that enzyme.

As used herein, the term "allele" refers to any of the alternative forms of a gene that may occur at a given locus.

As used herein, the term "α-Aminoadipate Reductase (EC 1.2.1.31), α-Aminoadipate Reductase polypeptide, α-Aminoadipate semialdehyde dehydrogenase, or Alpha-Aminoadipate Reductase" is synonymous with "the AAR1 gene product" or the "the ASD1 gene product" and refers to an enzyme that catalyses the interconversion of L-2-Aminoadipate, NADPH, and ATP with L-2-Aminoadipate 6-semialdehyde, NADP+, AMP, pyrophosphate, and H2O.

The term "antibiotic" refers to any substance or compound that when contacted with a living cell, organism, virus, or other entity capable of replication, results in a reduction of growth, viability, or pathogenicity of that entity.

The term "binding" refers to a non-covalent or a covalent interaction, preferably non-covalent, that holds two molecules together. For example, two such molecules could be an enzyme and an inhibitor of that enzyme. Non-covalent interactions include hydrogen bonding, ionic interactions among charged groups, van
der Waals interactions and hydrophobic interactions among nonpolar groups. One or more of these interactions can mediate the binding of two molecules to each other.

The term "biochemical pathway" or "pathway" refers to a connected series of biochemical reactions normally occurring in a cell, or more broadly a cellular event such as cellular division or DNA replication. Typically, the steps in such a biochemical pathway act in a coordinated fashion to produce a specific product or products or to produce some other particular biochemical action. Such a biochemical pathway requires the expression product of a gene if the absence of that expression product either directly or indirectly prevents the completion of one or more steps in that pathway, thereby preventing or significantly reducing the production of one or more normal products or effects of that pathway. Thus, an agent specifically inhibits such a biochemical pathway requiring the expression product of a particular gene if the presence of the agent stops or substantially reduces the completion of the series of steps in that pathway. Such an agent, may, but does not necessarily, act directly on the expression product of that particular gene.

As used herein, the term “cDNA” means complementary deoxyribonucleic acid.

As used herein, the term "CoA" means coenzyme A.

As used herein, the term “conditional lethal” refers to a mutation permitting growth and/or survival only under special growth or environmental conditions.

As used herein, the term “cosmid” refers to a hybrid vector, used in gene cloning, that includes a cos site (from the lambda bacteriophage). It also contains drug resistance marker genes and other plasmid genes. Cosmids are especially suitable for cloning large genes or multigene fragments.

As used herein, the term “dominant allele” refers to a dominant mutant allele in which a discernable mutant phenotype can be detected when this mutation is present in an organism that also contains a wild type (non-mutant), recessive allele, or other dominant allele.

As used herein, the term “DNA” means deoxyribonucleic acid.

As used herein, the term “ELISA” means enzyme-linked immunosorbent assay.

“Fungi” (singular: fungus) refers to whole fungi, fungal organs and tissues (e.g., asci, hyphae, pseudohyphae, rhizoid, sclerotia, sterigmata, spores, sporodochia, sporangia, synnemata, conidia, ascostroma, cleistothecia, mycelia, perithecia, basidia
and the like), spores, fungal cells and the progeny thereof. Fungi are a group of organisms (about 50,000 known species), including, but not limited to, mushrooms, mildews, moulds, yeasts, etc., comprising the kingdom Fungi. They can either exist as single cells or make up a multicellular body called a mycelium, which consists of filaments known as hyphae. Most fungal cells are multinucleate and have cell walls, composed chiefly of chitin. Fungi exist primarily in damp situations on land and, because of the absence of chlorophyll and thus the inability to manufacture their own food by photosynthesis, are either parasites on other organisms or saprotrophs feeding on dead organic matter. The principal criteria used in classification are the nature of the spores produced and the presence or absence of cross walls within the hyphae. Fungi are distributed worldwide in terrestrial, freshwater, and marine habitats. Some live in the soil. Many pathogenic fungi cause disease in animals and man or in plants, while some saprotrophs are destructive to timber, textiles, and other materials. Some fungi form associations with other organisms, most notably with algae to form lichens.

As used herein, the term "fungicide", "antifungal", or "antimycotic" refers to an antibiotic substance or compound that kills or suppresses the growth, viability, or pathogenicity of at least one fungus, fungal cell, fungal tissue or spore.

In the context of this disclosure, "gene" should be understood to refer to a unit of heredity. Each gene is composed of a linear chain of deoxyribonucleotides which can be referred to by the sequence of nucleotides forming the chain. Thus, "sequence" is used to indicate both the ordered listing of the nucleotides which form the chain, and the chain, itself, which has that sequence of nucleotides. ("Sequence" is used in the similar way in referring to RNA chains, linear chains made of ribonucleotides.)

The gene may include regulatory and control sequences, sequences which can be transcribed into an RNA molecule, and may contain sequences with unknown function. The majority of the RNA transcription products are messenger RNAs (mRNAs), which include sequences which are translated into polypeptides and may include sequences which are not translated. It should be recognized that small differences in nucleotide sequence for the same gene can exist between different fungal strains, or even within a particular fungal strain, without altering the identity of the gene.

As used in this disclosure, the terms "growth" or "cell growth" of an organism refers to an increase in mass, density, or number of cells of said organism. Some
common methods for the measurement of growth include the determination of the optical density of a cell suspension, the counting of the number of cells in a fixed volume, the counting of the number of cells by measurement of cell division, the measurement of cellular mass or cellular volume, and the like.

5 As used in this disclosure, the term "growth conditional phenotype" indicates that a fungal strain having such a phenotype exhibits a significantly greater difference in growth rates in response to a change in one or more of the culture parameters than an otherwise similar strain not having a growth conditional phenotype. Typically, a growth conditional phenotype is described with respect to a single growth culture parameter, such as temperature. Thus, a temperature (or heat-sensitive) mutant (i.e., a fungal strain having a heat-sensitive phenotype) exhibits significantly different growth, and preferably no growth, under non-permissive temperature conditions as compared to growth under permissive conditions. In addition, such mutants preferably also show intermediate growth rates at intermediate, or semi-permissive, temperatures. Similar responses also result from the appropriate growth changes for other types of growth conditional phenotypes.

As used herein, the term "H₂O" means water.

As used herein, the term "AAR1" means a gene encoding α-Aminoadipate Reductase activity, referring to an enzyme that catalyses the interconversion of L-2-Aminoadipate, NADPH, and ATP with L-2-Aminoadipate 6-semialdehyde, NADP+, AMP, pyrophosphate, and H₂O.

As used herein, the term "heterologous AAR1 gene" means a gene, not derived from Magnaporthe grisea, and having: at least 50% sequence identity, preferably 60%, 70%, 80%, 90%, 95%, 99% sequence identity and each integer unit of sequence identity from 50-100% in ascending order to SEQ ID NO: 1 or SEQ ID NO: 2; or at least 10% of the activity of a Magnaporthe grisea α-Aminoadipate Reductase, preferably 25%, 50%, 75%, 90%, 95%, 99% and each integer unit of activity from 10-100% in ascending order.

As used herein, the term "HCS1" means a gene encoding homocitrate synthase activity, referring to an enzyme that catalyses the interconversion of acetyl-CoA, H₂O, and 2-oxoglutarate with 2-hydroxybutane-1,2,4-tricarboxylate and CoA.

As used herein, the term "heterologous HCS1 gene" means a gene, not derived from Magnaporthe grisea, and having: at least 50% sequence identity, preferably
60%, 70%, 80%, 90%, 95%, 99% sequence identity and each integer unit of sequence identity from 50-100% in ascending order to SEQ ID NO: 1 or SEQ ID NO: 2; or at least 10% of the activity of a *Magnaporthe grisea* homocitrate synthase, preferably 25%, 50%, 75%, 90%, 95%, 99% and each integer unit of activity from 10-100% in ascending order.

As used herein, the term "homocitrate synthase (EC 4.1.3.21) or homocitrate synthase polypeptide" is synonymous with "the HCS1 gene product" and refers to an enzyme that catalyses the interconversion of acetyl-CoA, H₂O, and 2-oxoglutarate with 2-hydroxybutane-1,2,4-tricarboxylate and CoA.

As used herein, the term "His-Tag" refers to an encoded polypeptide consisting of multiple consecutive histidine amino acids.

As used herein, the term "HPLC" means high pressure liquid chromatography.

As used herein, the terms "hph", "hygromycin B phosphotransferase", and "hygromycin resistance gene" refer to the *E. coli* hygromycin phosphotransferase gene or gene product.

As used herein, the term "hygromycin B" refers to an aminoglycosidic antibiotic, used for selection and maintenance of eukaryotic cells containing the *E. coli* hygromycin resistance gene.

"Hypersensitive" refers to a phenotype in which cells are more sensitive to antibiotic compounds than are wild-type cells of similar or identical genetic background.

"Hyposensitive" refers to a phenotype in which cells are less sensitive to antibiotic compounds than are wild-type cells of similar or identical genetic background.

As used herein, the term "imperfect state" refers to a classification of a fungal organism having no demonstrable sexual life stage.

The term "inhibitor", as used herein, refers to a chemical substance that inactivates the enzymatic activity of α-Aminoadipate Reductase or Homocitrate Synthase, or substantially reduces the level of enzymatic activity, wherein "substantially" means a reduction at least as great as the standard deviation for a measurement, preferably a reduction by 50%, more preferably a reduction of at least one magnitude, i.e. to 10%. The inhibitor may function by interacting directly with
the enzyme, a cofactor of the enzyme, the substrate of the enzyme, or any combination thereof.

A polynucleotide may be "introduced" into a fungal cell by any means known to those of skill in the art, including transfection, transformation or transduction, transposable element, electroporation, particle bombardment, infection and the like. The introduced polynucleotide may be maintained in the cell stably if it is incorporated into a non-chromosomal autonomous replicon or integrated into the fungal chromosome. Alternatively, the introduced polynucleotide may be present on an extra-chromosomal non-replicating vector and be transiently expressed or transiently active.

As used herein, the term "knockout" or "gene disruption" refers to the creation of organisms carrying a null mutation (a mutation in which there is no active gene product), a partial null mutation or mutations, or an alteration or alterations in gene regulation by interrupting a DNA sequence through insertion of a foreign piece of DNA. Usually the foreign DNA encodes a selectable marker.

As used herein, the term "LB agar" means Luria's Broth agar.

The term "method of screening" means that the method is suitable, and is typically used, for testing for a particular property or effect in a large number of compounds. Typically, more than one compound is tested simultaneously (as in a 96-well microtiter plate), and preferably significant portions of the procedure can be automated. "Method of screening" also refers to determining a set of different properties or effects of one compound simultaneously.

As used herein, the term "mRNA" means messenger ribonucleic acid.

As used herein, the term "mutant form" of a gene refers to a gene which has been altered, either naturally or artificially, changing the base sequence of the gene. The change in the base sequence may be of several different types, including changes of one or more bases for different bases, deletions, and/or insertions, such as by a transposon. By contrast, a normal form of a gene (wild type) is a form commonly found in natural populations of an organism. Commonly a single form of a gene will predominate in natural populations. In general, such a gene is suitable as a normal form of a gene, however, other forms which provide similar functional characteristics may also be used as a normal gene. In particular, a normal form of a gene does not confer a growth conditional phenotype on the strain having that gene, while a mutant
form of a gene suitable for use in these methods does provide such a growth conditional phenotype.

As used herein, the term "Ni" refers to nickel.

As used herein, the term "Ni-NTA" refers to nickel sepharose.

As used herein, the term "one form" of a gene is synonymous with the term "gene", and a "different form" of a gene refers to a gene that has greater than 49% sequence identity and less than 100% sequence identity with said first form.

As used herein, the term "pathogenicity" refers to a capability of causing disease. The term is applied to parasitic microorganisms in relation to their hosts.

As used herein, the term "PCR" means polymerase chain reaction.

The "percent (%) sequence identity" between two polynucleotide or two polypeptide sequences is determined according to the either the BLAST program (Basic Local Alignment Search Tool; (Altschul, S.F., W. Gish, et al. (1990) J Mol Biol 215: 403 - 10 (PMID: 2231712)) at the National Center for Biotechnology or using Smith Waterman Alignment (Smith, T. F. and M. S. Waterman (1981) J Mol Biol 147: 195 - 7 (PMID: 7265238)) as incorporated into GeneMatcher Plus™. It is understood that for the purposes of determining sequence identity when comparing a DNA sequence to an RNA sequence, a thymine nucleotide is equivalent to a uracil nucleotide.

By "polypeptide" is meant a chain of at least two amino acids joined by peptide bonds. The chain may be linear, branched, circular or combinations thereof. Preferably, polypeptides are from about 10 to about 1000 amino acids in length, more preferably 10-50 amino acids in length. The polypeptides may contain amino acid analogs and other modifications, including, but not limited to glycosylated or phosphorylated residues.

As used herein, the term "proliferation" is synonymous to the term "growth".

As used herein, the term "reverse transcriptase-PCR" means reverse transcription-polymerase chain reaction.

As used herein, the term "RNA" means ribonucleic acid.

As used herein, "semi-permissive conditions" are conditions in which the relevant culture parameter for a particular growth conditional phenotype is intermediate between permissive conditions and non-permissive conditions. Consequently, in semi-permissive conditions an organism having a growth conditional phenotype will exhibit growth rates intermediate between those shown in
permissive conditions and non-permissive conditions. In general, such intermediate growth rate may be due to a mutant cellular component which is partially functional under semi-permissive conditions, essentially fully functional under permissive conditions, and is non-functional or has very low function under non-permissive conditions, where the level of function of that component is related to the growth rate of the organism. An intermediate growth rate may also be a result of a nutrient substance or substances that are present in amounts not sufficient for optimal growth rates to be achieved.

“Sensitivity phenotype” refers to a phenotype that exhibits either hypersensitivity or hyposensitivity.

The term “specific binding” refers to an interaction between α-Aminoadipate Reductase and a molecule or compound, wherein the interaction is dependent upon the primary amino acid sequence and/or the conformation of α-Aminoadipate Reductase.

As used herein, the term “TLC” means thin layer chromatography.

“Transform”, as used herein, refers to the introduction of a polynucleotide (single or double stranded DNA, RNA, or a combination thereof) into a living cell by any means. Transformation may be accomplished by a variety of methods, including, but not limited to, electroporation, polyethylene glycol mediated uptake, particle bombardment, agrotransformation, and the like. This process may result in transient or stable expression of the transformed polynucleotide. By “stably transformed” is meant that the sequence of interest is integrated into a replicon in the cell, such as a chromosome or episome. Transformed cells encompass not only the end product of a transformation process, but also the progeny thereof which retain the polynucleotide of interest.

For the purposes of the invention, “transgenic” refers to any cell, spore, tissue or part, that contains all or part of at least one recombinant polynucleotide. In many cases, all or part of the recombinant polynucleotide is stably integrated into a chromosome or stable extra-chromosomal element, so that it is passed on to successive generations.

As used herein, the term “transposase” refers to an enzyme that catalyzes transposition. Preferred transposons are described in WO 00/55346, PCT/US00/07317, and US 09/658859.
As used herein, the term "transposition" refers to a complex genetic rearrangement process involving the movement or copying of a polynucleotide (transposon) from one location and insertion into another, often within or between a genome or genomes, or DNA constructs such as plasmids, bacmids, and cosmids.

As used herein, the term "transposon" (also known as a "transposable element", "transposable genetic element", "mobile element", or "jumping gene") refers to a mobile DNA element such as those, for example, described in WO 00/55346, PCT/US00/07317, and US 09/658859. Transposons can disrupt gene expression or cause deletions and inversions, and hence affect both the genotype and phenotype of the organisms concerned. The mobility of transposable elements has long been used in genetic manipulation, to introduce genes or other information into the genome of certain model systems.

As used herein, the term "Tween 20" means sorbitan mono-9-octadecenoate poly(oxy-1,1-ethanediyl).

As used in this disclosure, the term "viability" of an organism refers to the ability of an organism to demonstrate growth under conditions appropriate for said organism, or to demonstrate an active cellular function. Some examples of active cellular functions include respiration as measured by gas evolution, secretion of proteins and/or other compounds, dye exclusion, mobility, dye oxidation, dye reduction, pigment production, changes in medium acidity, and the like.

The present inventors have discovered that disruption of the AAR1 or HCS1 gene and/or gene product inhibits the pathogenicity of Magnaporthe grisea. Thus, the inventors are the first to demonstrate that α-Aminoacidipate Reductase and Homocitrate Synthase are targets for antibiotics, preferably antifungals.

Accordingly, the invention provides methods for identifying compounds that inhibit AAR1 or HCS1 gene expression or biological activity of its gene product(s). Such methods include ligand binding assays, assays for enzyme activity, cell-based assays, and assays for AAR1 or HSC1 gene expression. Any compound that is a ligand for α-Aminoacidipate Reductase or for Homocitrate Synthase may have antibiotic activity. For the purposes of the invention, "ligand" refers to a molecule that will bind to a site on a polypeptide. The compounds identified by the methods of the invention are useful as antibiotics.
Thus, in one embodiment, the invention provides a method for identifying a
(test) compound as a candidate for an antibiotic, comprising:

a) contacting at least one polypeptide selected from the group consisting of:
   i) \(\alpha\)-Aminoadipate Reductase; and
   ii) Homocitrinate Synthase

with said test compound; and

b) detecting the presence or absence of binding between said test compound and
said polypeptide; wherein binding indicates that said test compound is a
candidate for an antibiotic.

The \(\alpha\)-Aminoadipate Reductase or Homocitrinate Synthase protein may have the amino
acid sequence of a naturally occurring \(\alpha\)-Aminoadipate Reductase or Homocitrinate
Synthase found in a fungus, animal, plant, or microorganism, or may have an amino
acid sequence derived from a naturally occurring sequence. Preferably the \(\alpha\)-
Aminoadipate Reductase or Homocitrinate Synthase is a fungal \(\alpha\)-Aminoadipate
Reductase or Homocitrinate Synthase. The cDNA (SEQ ID NO: 1) encoding the \(\alpha\)-
Aminoadipate Reductase protein, the genomic DNA (SEQ ID NO: 2) encoding the
protein, and the polypeptide (SEQ ID NO: 3) can be found herein. The cDNA (SEQ
ID NO: 4) encoding the Homocitrinate Synthase protein, the genomic DNA (SEQ ID
NO: 5) encoding the protein, and the polypeptide (SEQ ID NO: 6) can be found
herein, as well.

By "fungal \(\alpha\)-Aminoadipate Reductase" is meant an enzyme that can be
found in at least one fungus, and which catalyzes the interconversion of L-2-
Aminoadipate and NADPH and ATP with L-2-Aminoadipate 6-semialdehyde,
NADP+, AMP, pyrophosphate, and \(H_2O\). The \(\alpha\)-Aminoadipate Reductase may be
from any of the fungi, including ascomycota, zygomycota, basidiomycota,
chytridiomycota, and lichens.

By "fungal Homocitrinate Synthase" is meant an enzyme that can be found in at
least one fungus, and which catalyzes the interconversion of acetyl-CoA and \(H_2O\) and
2-oxoglutarate with 2-hydroxybutane-1,2,4-tricarboxylate and CoA. The homocitrinate
synthase may be from any of the fungi, including ascomycota, zygomycota,
basidiomycota, chytridiomycota, and lichens.

In one embodiment, the \(\alpha\)-Aminoadipate Reductase or Homocitrinate Synthase
is a \textit{Magnaporthe} \(\alpha\)-Aminoadipate Reductase or Homocitrinate Synthase.
Magnaporthe species include, but are not limited to, Magnaporthe rhizophila, Magnaporthe salvinii, Magnaporthe grisea and Magnaporthe poae and the imperfect states of Magnaporthe in the genus Pyricularia. Preferably, the Magnaporthe α-Aminoadipate Reductase or Homocitrate Synthase is from Magnaporthe grisea.

In various embodiments, the α-Aminoadipate Reductase or Homocitrate Synthase can be from Powdery Scab (Spongospora subterranea), Grey Mould (Botrytis cinerea), White Rot (Armillaria mellea), Heartrot Fungus (Ganoderma adspersum), Brown-Rot (Piptoporus betulinus), Corn Smut (Ustilago maydis), Heartrot (Polyporus squamosus), Gray Leaf Spot (Cercospora zeae-maydis), Honey Fungus (Armillaria gallica), Root rot (Armillaria luteobubalina), Shoestring Rot (Armillaria ostoyae), Banana Anthracnose Fungus (Colletotrichum musae), Apple-rotting Fungus (Monilinia fructigena), Apple-rotting Fungus (Penicillium expansum), Clubroot Disease (Plasmidothora brassicae), Potato Blight (Phytophthora infestans), Root pathogen (Heterobasidion annosum), Take-all Fungus (Gaumannomyces graminis), Dutch Elm Disease (Ophiostoma ulmi), Bean Rust (Uromyces appendiculatus), Northern Leaf Spot (Cochliobolus carbonum), Milo Disease (Periconia circinata), Southern Corn Blight (Cochliobolus heterostrophus), Leaf Spot (Cochliobolus lunata), Brown Stripe (Cochliobolus stenospilus), Panama disease (Fusarium oxysporum), Wheat Head Scab Fungus (Fusarium graminearum), Cereal Foot Rot (Fusarium culmorum), Potato Black Scurf (Rhizoctonia solani), Wheat Black Stem Rust (Puccinia graminis), White mold (Sclerotinia sclerotiorum), and the like.

Fragments of an α-Aminoadipate Reductase or Homocitrate Synthase polypeptide may be used in the methods of the invention, preferably if the fragments include an intact or nearly intact epitope that occurs on the biologically active wildtype α-Aminoadipate Reductase or Homocitrate Synthase. The fragments comprise at least 10 consecutive amino acids of an α-Aminoadipate Reductase or Homocitrate Synthase. Preferably, the fragment comprises at least 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890,
900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1010, 1020, 1030, 1040,
1050, 1060, 1070, 1080, 1090, 1100, 1110, 1120, 1130, 1140, 1150, 1160, 1170, or at
least 1180 consecutive amino acids residues of an α-Aminoadipate Reductase or
Homocitrate Synthase. In one embodiment, the fragment is from a Magnaporthe α-
5 Aminoadipate Reductase or Homocitrate Synthase. Preferably, the fragment contains
an amino acid sequence conserved among fungal α-Aminoadipate Reductases or
Homocitrate Synthases.

Polypeptides having at least 50% sequence identity with a fungal α-
Aminoadipate Reductase or Homocitrate Synthase are also useful in the methods of
10 the invention. Preferably, the sequence identity is at least 60%, more preferably the
sequence identity is at least 70%, most preferably the sequence identity is at least 80%
or 90 or 95 or 99%, or any integer from 60-100% sequence identity in ascending
order.

In addition, it is preferred that the polypeptide has at least 10% of the activity
of a fungal α-Aminoadipate Reductase or Homocitrate Synthase. More preferably,
15 the polypeptide has at least 25%, at least 50%, at least 75% or at least 90% of the
activity of a fungal α-Aminoadipate Reductase or Homocitrate Synthase. Most
preferably, the polypeptide has at least 10%, at least 25%, at least 50%, at least 75%
or at least 90% of the activity of the M. grisea α-Aminoadipate Reductase or
Homocitrate Synthase protein.

Thus, in another embodiment, the invention provides a method for identifying
a test compound as a candidate for a fungicide, comprising:

a) contacting said test compound with at least one polypeptide selected from the
group consisting of: a polypeptide having at least ten consecutive amino acids
20 of a fungal α-Aminoadipate Reductase, a polypeptide having at least 50%
sequence identity with a fungal α-Aminoadipate Reductase, and a polypeptide
having at least 10% of the activity thereof; and
b) detecting the presence and/or absence of binding between said test compound
and said polypeptide;

wherein binding indicates that said test compound is a candidate for an antibiotic.

In still another embodiment, the invention provides a method for identifying a
test compound as a candidate for a fungicide, comprising:
a) contacting said test compound with at least one polypeptide selected from the
   group consisting of: a polypeptide having at least ten consecutive amino acids
   of a fungal homocitrate synthase, a polypeptide having at least 50% sequence
   identity with a fungal homocitrate synthase, and a polypeptide having at least
   10% of the activity thereof; and

b) detecting the presence and/or absence of binding between said test compound
   and said polypeptide;

   wherein binding indicates that said test compound is a candidate for an antibiotic.

   Any technique for detecting the binding of a ligand to its target may be used in
   the methods of the invention. For example, the ligand and target are combined in a
   buffer. Many methods for detecting the binding of a ligand to its target are known in
   the art, and include, but are not limited to the detection of an immobilized ligand-
   target complex or the detection of a change in the properties of a target when it is
   bound to a ligand. For example, in one embodiment, an array of immobilized
   candidate ligands is provided. The immobilized ligands are contacted with an α-
   Aminoadipate Reductase or Homocitrate Synthase protein or a fragment or variant
   thereof, the unbound protein is removed and the bound α-Aminoadipate Reductase is
   detected. In a preferred embodiment, bound α-Aminoadipate Reductase or
   Homocitrate Synthase is detected using a labeled binding partner, such as a labeled
   antibody. In a variation of this assay, α-Aminoadipate Reductase or Homocitrate
   Synthase is labeled prior to contacting the immobilized candidate ligands. Preferred
   labels include fluorescent or radioactive moieties. Preferred detection methods include
   fluorescence correlation spectroscopy (FCS) and FCS-related confocal
   nanofluorimetric methods.

   Once a compound is identified as a candidate for an antibiotic, it can be tested
   for the ability to inhibit α-Aminoadipate Reductase or Homocitrate Synthase
   enzymatic activity. The compounds can be tested using either in vitro or cell based
   assays. Alternatively, a compound can be tested by applying it directly to a fungus or
   fungal cell, or expressing it therein, and monitoring the fungus or fungal cell for
   changes or decreases in growth, development, viability, pathogenicity, or alterations
   in gene expression. Thus, in one embodiment, the invention provides a method for
determining whether a compound identified as an antibiotic candidate by an above
method has antifungal activity, further comprising: contacting a fungus or fungal cells
with said antifungal candidate and detecting a decrease in the growth, viability, or pathogenicity of said fungus or fungal cells.

By decrease in growth, is meant that the antifungal candidate causes at least a 10% decrease in the growth of the fungus or fungal cells, as compared to the growth of the fungus or fungal cells in the absence of the antifungal candidate. By a decrease in viability is meant that at least 20% of the fungal cells, or portion of the fungus contacted with the antifungal candidate are nonviable. Preferably, the growth or viability will be decreased by at least 40%. More preferably, the growth or viability will be decreased by at least 50%, 75% or at least 90% or more. Methods for measuring fungal growth and cell viability are known to those skilled in the art. By decrease in pathogenicity, is meant that the antifungal candidate causes at least a 10% decrease in the disease caused by contact of the fungal pathogen with its host, as compared to the disease caused in the absence of the antifungal candidate. Preferably, the disease will be decreased by at least 40%. More preferably, the disease will be decreased by at least 50%, 75% or at least 90% or more. Methods for measuring fungal disease are well known to those skilled in the art, and include such metrics as lesion formation, lesion size, sporulation, respiratory failure, and/or death.

The ability of a compound to inhibit α-Aminoadipate Reductase activity can be detected using in vitro enzymatic assays in which the disappearance of a substrate or the appearance of a product is directly or indirectly detected. α-Aminoadipate Reductase catalyzes the irreversible or reversible reaction L-2-Aminoadipate and NADPH and ATP → L-2-Aminoadipate 6-semialdehyde, NADP+, AMP, pyrophosphate, and H₂O (see Figure 1). Methods for detection of L-2-Aminoadipate, L-2-Aminoadipate 6-semialdehyde, NADP+, NADPH, AMP, ATP, H₂O and/or pyrophosphate, include spectrophotometry, mass spectroscopy, thin layer chromatography (TLC) and reverse phase HPLC.

Thus, the invention provides a method for identifying a test compound as a candidate for an antibiotic, comprising either:

a) contacting L-2-Aminoadipate and NADPH and ATP with an α-Aminoadipate Reductase;

b) contacting L-2-Aminoadipate and NADPH and ATP with α-Aminoadipate Reductase and said test compound; and
c) determining the change in concentration for at least one of the following: L-2-Aminoadipate, L-2-Aminoadipate 6-semialdehyde, NADP⁺, NADPH, AMP, ATP, H₂O and/or pyrophosphate.

wherein a change in concentration for any of the above substances indicates that said test compound is a candidate for an antibiotic.

or,

a) contacting L-2-Aminoadipate 6-semialdehyde, NADP⁺, AMP, pyrophosphate, and H₂O with an α-Aminoadipate Reductase;

b) contacting L-2-Aminoadipate 6-semialdehyde, NADP⁺, AMP, pyrophosphate, and H₂O with an α-Aminoadipate Reductase and said test compound; and

c) determining the change in concentration for at least one of the following: L-2-Aminoadipate, L-2-Aminoadipate 6-semialdehyde, NADP⁺, NADPH, AMP, ATP, H₂O and/or pyrophosphate.

wherein a change in concentration for any of the above substances indicates that said test compound is a candidate for an antibiotic.

The ability of a compound to inhibit homocitrate synthase activity can be detected using in vitro enzymatic assays in which the disappearance of a substrate or the appearance of a product is directly or indirectly detected. Homocitrate synthase catalyzes the irreversible or reversible reaction acetyl-CoA and H₂O and 2-oxoglutarate = 2-hydroxybutane-1,2,4-tricarboxylate and CoA (see Figure 4). Methods for detection of 2-hydroxybutane-1,2,4-tricarboxylate, CoA, acetyl-CoA, and/or 2-oxoglutarate, include spectrophotometry, mass spectroscopy, thin layer chromatography (TLC) and reverse phase HPLC.

Thus, the invention provides a method for identifying a test compound as a candidate for an antibiotic, comprising either:

a) contacting acetyl-CoA and H₂O and 2-oxoglutarate with a homocitrate synthase;

b) contacting acetyl-CoA and H₂O and 2-oxoglutarate with homocitrate synthase and said test compound; and

c) determining the change in concentration for at least one of the following: 2-hydroxybutane-1,2,4-tricarboxylate, 2-oxoglutarate, acetyl-CoA, CoA, and/or H₂O.

wherein a change in concentration for any of the above substances indicates that said test compound is a candidate for an antibiotic.
or,

a) contacting 2-hydroxybutane-1,2,4-tricarboxylate and CoA with a homocitrate synthase;

b) contacting 2-hydroxybutane-1,2,4-tricarboxylate and CoA with a homocitrate synthase and said test compound; and

c) determining the change in concentration for at least one of the following: 2-hydroxybutane-1,2,4-tricarboxylate, 2-oxoglutarate, acetyl-CoA, CoA, and/or H₂O. wherein a change in concentration for any of the above substances indicates that said test compound is a candidate for an antibiotic.

Enzymatically active fragments of a fungal α-Aminoadipate Reductase or Homocitrate Synthase are also useful in the methods of the invention. For example, a polypeptide comprising at least 100 consecutive amino acid residues of a fungal α-Aminoadipate Reductase or Homocitrate Synthase may be used in the methods of the invention. In addition, a polypeptide having at least 50%, 60%, 70%, 80%, 90%, 95% or at least 98% sequence identity with a fungal α-Aminoadipate Reductase or Homocitrate Synthase may be used in the methods of the invention. Most preferably, the polypeptide has at least 50% sequence identity with a fungal α-Aminoadipate Reductase or Homocitrate Synthase and at least 10%, 25%, 75% or at least 90% of the activity thereof.

Thus, the invention provides a method for identifying a test compound as a candidate for a fungicide, comprising:

a) contacting L-2-Aminoadipate and NADPH and ATP with a polypeptide selected from the group consisting of: a polypeptide having at least 50% sequence identity with an α-Aminoadipate Reductase, a polypeptide having at least 50% sequence identity with an α-Aminoadipate Reductase and having at least 10% of the activity thereof, and a polypeptide comprising at least 100 consecutive amino acids of an α-Aminoadipate Reductase

b) contacting L-2-Aminoadipate and NADPH and ATP with said polypeptide and said test compound; and

c) determining the change in concentration for at least one of the following: L-2-Aminoadipate, L-2-Aminoadipate 6-semialdehyde, NADP⁺, NADPH, AMP, ATP, H₂O and/or pyrophosphate.
wherein a change in concentration for any of the above substances indicates that said test compound is a candidate for an antibiotic.

or,

a) contacting L-2-Aminoadipate 6-semialdehyde, NADP+, AMP, pyrophosphate, and H₂O with a polypeptide selected from the group consisting of: a polypeptide having at least 50% sequence identity with an α-Aminoadipate Reductase, a polypeptide having at least 50% sequence identity with an α-Aminoadipate Reductase and at least 10% of the activity thereof, and a polypeptide comprising at least 100 consecutive amino acids of an α-Aminoadipate Reductase.

b) contacting L-2-Aminoadipate 6-semialdehyde, NADP+, AMP, pyrophosphate, and H₂O, with said polypeptide and said test compound; and

c) determining the change in concentration for at least one of the following: L-2-Aminoadipate, L-2-Aminoadipate 6-semialdehyde, NADP+, NADPH, AMP, ATP, H₂O and/or pyrophosphate;

wherein a change in concentration for any of the above substances indicates that said test compound is a candidate for an antibiotic.

Additionally, the invention provides a method for identifying a test compound as a candidate for a fungicide, comprising:

a) contacting acetyl-CoA and H₂O and 2-oxoglutarate with a polypeptide selected from the group consisting of: a polypeptide having at least 50% sequence identity with a homocitrate synthase, a polypeptide having at least 50% sequence identity with a homocitrate synthase and having at least 10% of the activity thereof, and a polypeptide comprising at least 100 consecutive amino acids of a homocitrate synthase.

b) contacting acetyl-CoA and H₂O and 2-oxoglutarate with said polypeptide and said test compound; and

c) determining the change in concentration for at least one of the following: 2-hydroxybutane-1,2,4-tricarboxylate, 2-oxoglutarate, acetyl-CoA, CoA, and/or H₂O.

wherein a change in concentration for any of the above substances indicates that said test compound is a candidate for an antibiotic.

or,
a) contacting 2-hydroxybutane-1,2,4-tricarboxylate and CoA with a polypeptide selected from the group consisting of: a polypeptide having at least 50% sequence identity with a homocitrate synthase, a polypeptide having at least 50% sequence identity with a homocitrate synthase and at least 10% of the activity thereof, and a polypeptide comprising at least 100 consecutive amino acids of a homocitrate synthase
b) contacting 2-hydroxybutane-1,2,4-tricarboxylate and CoA, with said polypeptide and said test compound; and
c) determining the change in concentration for at least one of the following, 2-hydroxybutane-1,2,4-tricarboxylate, 2-oxoglutarate, acetyl-CoA, CoA, and/or H₂O.

wherein a change in concentration for any of the above substances indicates that said test compound is a candidate for an antibiotic.

For the in vitro enzymatic assays, α-Aminoadipate Reductase or Homocitrate Synthase protein and derivatives thereof may be purified from a fungus or may be recombinantly produced in and purified from an archael, bacterial, fungal, or other eukaryotic cell culture. Preferably these proteins are produced using an E. coli, yeast, or filamentous fungal expression system. Methods for the purification of α-Aminoadipate Reductase or Homocitrate Synthase may be described in Jaklitsch and Kubicek (Jaklitsch, W. M. and C. P. Kubicek (1990) Biochem J 269: 247 - 53 (PMID: 2115771)). Other methods for the purification of α-Aminoadipate Reductase or Homocitrate Synthase proteins and polypeptides are known to those skilled in the art.

As an alternative to in vitro assays, the invention also provides cell based assays. In one embodiment, the invention provides a method for identifying a test compound as a candidate for an antibiotic, comprising:

a) measuring the expression of an α-Aminoadipate Reductase or Homocitrate Synthase in a cell, cells, tissue, or an organism in the absence of said compound;

b) contacting said cell, cells, tissue, or organism with said test compound and measuring the expression of said α-Aminoadipate Reductase or Homocitrate Synthase in said cell, cells, tissue, or organism;
c) comparing the expression of α-Aminoadipate Reductase or Homocitrate Synthase in steps (a) and (b); wherein a lower expression in the presence of said test compound indicates that said compound is a candidate for an antibiotic.

Expression of α-Aminoadipate Reductase or Homocitrate Synthase can be measured by detecting the AAR1 or HCS1 primary transcript or mRNA, α-Aminoadipate Reductase or Homocitrate Synthase polypeptide, or α-Aminoadipate Reductase or Homocitrate Synthase enzymatic activity. Methods for detecting the expression of RNA and proteins are known to those skilled in the art. See, for example, *Current Protocols in Molecular Biology* Ausubel et al., eds., Greene Publishing and Wiley-Interscience, New York, 1995. The method of detection is not critical to the invention. Methods for detecting AAR1 RNA include, but are not limited to amplification assays such as quantitative reverse transcriptase-PCR, and/or hybridization assays such as Northern analysis, dot blots, slot blots, in-situ hybridization, transcriptional fusions using an AAR1 or HCS1 promoter fused to a reporter gene, DNA assays, and microarray assays.

Methods for detecting protein expression include, but are not limited to, immunodetection methods such as Western blots, ELISA assays, polyacrylamide gel electrophoresis, mass spectroscopy, and enzymatic assays. Also, any reporter gene system may be used to detect AAR1 or HCS1 protein expression. For detection using gene reporter systems, a polynucleotide encoding a reporter protein is fused in frame with AAR1 or HCS1, so as to produce a chimeric polypeptide. Methods for using reporter systems are known to those skilled in the art.

Chemicals, compounds or compositions identified by the above methods as modulators, preferably inhibitors, of AAR1 or HCS1 expression or activity can then be used to control fungal growth. Diseases such as rusts, mildews, and blights spread rapidly once established. Fungicides are thus routinely applied to growing and stored crops as a preventive measure, generally as foliar sprays or seed dressings. For example, compounds that inhibit fungal growth can be applied to a fungus or expressed in a fungus, in order to prevent fungal growth. Thus, the invention provides a method for inhibiting fungal growth, comprising contacting a fungus with a compound identified by the methods of the invention as having antifungal activity.
Antifungals and antifungal inhibitor candidates identified by the methods of
the invention can be used to control the growth of undesired fungi, including
ascomycota, zygomycota, basidiomycota, chytridiomycota, and lichens.

Examples of undesired fungi include, but are not limited to Powdery Scab
(Spongospora subterranea), Grey Mould (Botrytis cinerea), White Rot (Armillaria
mellea), Heartrot Fungus (Ganoderma adspersum), Brown-Rot (Piptoporus
betulinus), Corn Smut (Ustilago maydis), Heartrot (Polyporus squamosus), Gray Leaf
Spot (Cercospora zeae-maydis), Honey Fungus (Armillaria gallica), Root rot
(Armillaria luteobulalina), Shoestring Rot (Armillaria ostoyae), Banana Anthracnose
Fungus (Colletotrichum musae), Apple-rotting Fungus (Monilinia fructigena), Apple-
rotting Fungus (Penicillium expansum), Clubroot Disease (Plasmodiophora
brassicae), Potato Blight (Phytophthora infestans), Root pathogen (Heterobasidion
annosum), Take-all Fungus (Gaemammomycyes graminis), Dutch Elm Disease
(Ophiostoma ulmi), Bean Rust (Uromyces appendiculatus), Northern Leaf Spot
(Cochliobolus carbonum), Milo Disease (Periconia circinata), Southern Corn Blight
(Cochliobolus heterostrophus), Leaf Spot (Cochliobolus lunata), Brown Stripe
(Cochliobolus stenosplius), Panama disease (Fusarium oxysporum), Wheat Head Scab
Fungus (Fusarium graminearum), Cereal Foot Rot (Fusarium culmorum), Potato
Black Scurf (Rhizoctonia solani), Wheat Black Stem

Rust (Puccinia graminis), White mold (Sclerotinia sclerotiorum), diseases of animals
such as infections of lungs, blood, brain, skin, scalp, nails or other tissues (Aspergillus
fumigatus Aspergillus sp. Fusarium sp., Trichophyton sp., Epidermophyton sp., and
Microsporum sp., and the like).

Also provided is a method of screening for an antibiotic by determining
whether a test compound is active against the gene identified (SEQ ID NO: 1 and
SEQ ID NO: 2 for AAR1, or SEQ ID NO: 4 and SEQ ID NO: 5 for HCS1), its gene
product (SEQ ID NO: 3 for AAR1 or SEQ ID NO: 6 for HCS1), or the biochemical
pathway or pathways on which it functions.

In one particular embodiment, the method is performed by providing an
organism having a first form of the gene corresponding to either SEQ ID NO: 1 or
SEQ ID NO: 2 for AAR1, or SEQ ID NO: 4 and SEQ ID NO: 5 for HCS1, either a
normal form, a mutant form, a homologue, or a heterologous AAR1 or HCS1 gene
that performs a similar function as AAR1 or HCS1, respectively. The first form of
AAR1 or HCS1 may or may not confer a growth conditional phenotype, i.e., a lysine
requiring phenotype, and/or a hypersensitivity or hyposensitivity phenotype on the organism having that altered form. In one particular embodiment a mutant form contains a transposon insertion. A comparison organism having a second form of an AAR1 or HCS1, different from the first form of the gene is also provided, and the two organisms are separately contacted with a test compound. The growth of the two AAR1 or HCS1 organisms in the presence of the test compound is then compared.

Thus, in one embodiment, the invention provides a method for identifying a test compound as a candidate for an antibiotic, comprising:

a) providing cells having one form of an α-Aminoadipate Reductase gene, and providing comparison cells having a different form of an α-Aminoadipate Reductase gene,

b) contacting said cells and said comparison cells with a test compound and determining the growth of said cells and comparison cells in the presence of the test compound,

wherein a difference in growth between said cells and said comparison cells in the presence of said test compound indicates that said test compound is a candidate for an antibiotic.

In another embodiment, the invention provides a method for identifying a test compound as a candidate for an antibiotic, comprising:

a) providing cells having one form of a Homocitrate Synthase gene, and providing comparison cells having a different form of a Homocitrate Synthase gene,

b) contacting said cells and said comparison cells with a test compound and determining the growth of said cells and comparison cells in the presence of the test compound,

wherein a difference in growth between said cells and said comparison cells in the presence of said test compound indicates that said test compound is a candidate for an antibiotic.

It is recognized in the art that the optional determination of the growth of said first organism and said comparison second organism in the absence of any test compounds may be performed to control for any inherent differences in growth as a result of the different genes. It is also recognized that any combination of two different forms of an AAR1 gene or an HCS1 gene, including normal genes, mutant genes, homologues, and functional homologues may be used in this method. Growth
and/or proliferation of an organism is measured by methods well known in the art such as optical density measurements, and the like. In a preferred embodiment the organism is Magnaporthe grisea.

Conditional lethal mutants may identify particular biochemical and/or genetic pathways given that at least one identified target gene is present in that pathway. Knowledge of these pathways allows for the screening of test compounds as candidates for antibiotics as inhibitors of the substrates, products and enzymes of the pathway. Pathways known in the art may be found at the Kyoto Encyclopedia of Genes and Genomes and in standard biochemistry texts (Lehninger, A., D. Nelson, et al. (1993) Principles of Biochemistry. New York, Worth Publishers).

Thus, in one embodiment, the invention provides a method for screening for test compounds acting against the biochemical and/or genetic pathway or pathways in which AAR1 or HCS1 functions, comprising:

a) providing cells having one form of a gene in the lysine biochemical and/or genetic pathway and providing comparison cells having a different form of said gene;

b) contacting said cells and comparison cells with a said test compound; and

c) determining the growth of said cells and comparison cells in the presence of said test compound, wherein a difference in growth between said cells and said comparison cells in the presence of said compound indicates that said compound is a candidate for an antibiotic.

The use of multi-well plates for screening is a format that readily accommodates multiple different assays to characterize various compounds, concentrations of compounds, and fungal strains in varying combinations and formats. Certain testing parameters for the screening method can significantly affect the identification of growth inhibitors, and thus can be manipulated to optimize screening efficiency and/or reliability. Notable among these factors are variable sensitivities of different mutants, increasing hypersensitivity with increasingly less permissive conditions, an apparent increase in hypersensitivity with increasing compound concentration, and other factors known to those in the art.

Conditional lethal mutants may identify particular biochemical and/or genetic pathways given that at least one identified target gene is present in that pathway. Knowledge of these pathways allows for the screening of test compounds as candidates for antibiotics. Pathways known in the art may be found at the Kyoto
Encyclopedia of Genes and Genomes and in standard biochemistry texts (Lehninger, A., D. Nelson, et al. (1993) *Principles of Biochemistry*. New York, Worth Publishers). Thus, in one embodiment, the invention provides a method for screening for test compounds acting against the biochemical and/or genetic pathway or pathways in which AAR1 or HCS1 functions, comprising:

(a) providing paired growth media; comprising a first medium and a second medium, wherein said second medium contains a higher level of lysine than said first medium;

(b) contacting an organism with said test compound;

(c) inoculating said first and second media with said organism; and

(d) determining the growth of said organism; wherein a difference in growth of the organism between said first and second media indicates that said test compound is a candidate for an antibiotic.

It is recognized in the art that the optional determination of the growth of said organism in the paired media in the absence of any test compounds may be performed to control for any inherent differences in growth as a result of the different media. Growth and/or proliferation of an organism is measured by methods well known in the art such as optical density measurements, and the like. In a preferred embodiment, the organism is *Magnaporthe grisea*.

**EXPERIMENTAL**

Example 1

Construction of Plasmids with a Transposon Containing a Selectable Marker.

Construction of Sif transposon: Sif was constructed using the GPS3 vector from the GPS-M mutagenesis system from New England Biolabs, Inc. (Beverly, MA) as a backbone. This system is based on the bacterial transposon Tn7. The following manipulations were done to GPS3 according to Sambrook *et al.* (1989) *Molecular Cloning, a Laboratory Manual*, Cold Spring Harbor Laboratory Press. The kanamycin resistance gene (npt) contained between the Tn7 arms was removed by EcoRV digestion. The bacterial hygromycin B phosphotransferase (hph) gene (Gritz and Davies (1983) *Gene* 25: 179 – 88 (PMID: 6319235)) under control of the *Aspergillus nidulans* trpC promoter and terminator (Mullaney *et al.* (1985) Mol Gen Genet 199: 29
37 – 45 (PMID: 3158796)) was cloned by a HpaI/EcoRV blunt ligation into the Tn7 arms of the GPS3 vector yielding pSif1. Excision of the ampicillin resistance gene (bla) from pSif1 was achieved by cutting pSif1 with XmnI and BglII followed by a T4 DNA polymerase treatment to remove the 3’ overhangs left by the BglII digestion and religation of the plasmid to yield pSif. Top 10F’ electrocompetent E. coli cells (Invitrogen) were transformed with ligation mixture according to manufacturer’s recommendations. Transformants containing the Sif transposon were selected on LB agar (Sambrook et al. (1989) Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory Press.) containing 50ug/ml of hygromycin B (Sigma Chem. Co., St. Louis, MO).

Example 2
Construction of a Cosmid Library Containing Fungal Genes and a Selectable Marker

Cosmid libraries were constructed in the pcosKA5 vector (Hamer et al. (2001) Proc Natl Acad Sci USA 98: 5110 – 15 (PMID: 11296265)) as described in Sambrook et al. (1989) Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory Press. Cosmid libraries were quality checked by pulsed-field gel electrophoresis, restriction digestion analysis, and PCR identification of single genes.

Example 3
Construction of Cosmids with Transposon Inserted into Fungal Genes.

Sif Transposition into a Cosmid: Transposition of Sif into the cosm id framework was carried out as described by the GPS-M mutagenesis system (New England Biolabs, Inc.). Briefly, 2ul of the 10X GPS buffer, 70 ng of supercoiled pSIF, 8-12 µg of target cosm id DNA were mixed and taken to a final volume of 20ul with water. 1ul of transposase (TnsABC) was added to the reaction and incubated for 10 minutes at 37°C to allow the assembly reaction to happen. After the assembly reaction 1ul of start solution was added to the tube, mixed well and incubated for 1 hour at 37°C followed by heat inactivation of the proteins at 75°C for 10 min. Destruction of the remaining untransposed pSif was done by PlsceI digestion at 37°C for 2 hours followed by 10 min incubation at 75°C to inactivate the proteins. Transformation of Top10F’ electrocompetent cells (Invitrogen) was done according to
manufacturers recommendations. Sif-containing cosmid transformants were selected by growth on LB agar plates containing 50ug/ml of hygromycin B (Sigma Chem. Co.) and 100 ug/ml of Ampicillin (Sigma Chem. Co.).

Example 4
High Throughput Preparation and Verification of Insertion of Transposon into Fungal Genes

E. coli strains containing cosmids with transposon insertions were picked to 96 well growth blocks (Beckman Co.) containing 1.5 ml of TB (Terrific Broth, Sambrook et al. (1989) Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory Press) supplemented with 50 ug/ml of ampicillin. Blocks were incubated with shaking at 37 C overnight. E. coli cells were pelleted by centrifugation and cosmids were isolated by a modified alkaline lysis method (Marra et al. (1997) Genome Res 7: 1072 – 84 (PMID: 9371743)). DNA quality was checked by electrophoresis on agarose gels. Cosmids were sequenced using primers from the ends of each transposon and commercial deoxy sequencing kits (Big Dye Terminators, Perkin Elmer Co.). Sequencing reactions were analyzed on an ABI377 DNA sequencer (Perkin Elmer Co.).

DNA sequences adjacent to the site of the insertion were collected and used to search DNA and protein databases using the BLAST algorithms (Altschul et al. (1997) Nucleic Acids Res 25: 3389 – 3402 (PMID: 9254694)). A single insertion of SIF into the Magnaporthe grisea AAR1 gene was chosen for further analysis. This construct was designated cpgmra0015019g12 and it contains the SIF transposon approximately between amino acids 678 and 679 relative to the Neurospora crassa homologue (total length - 1174 amino acids, GENBANK: 9367248 of accession number AL389890).

As for AAR1 above, DNA sequences adjacent to the site of the insertion were collected and used to search DNA and protein databases using the BLAST algorithms (Altschul et al. (1997) Nucleic Acids Res 25: 3389 – 3402 (PMID: 9254694)). A single insertion of SIF into the Magnaporthe grisea HCS1 gene was chosen for further analysis. This construct was designated cpgmra0023008h04 and it contains the SIF transposon between amino acids 334 and 335 relative to the Penicillium
chrysogenum homologue (total length - 474 amino acids, GENBANK: PCAJ3630
accession number AJ223630).

Example 5
Preparation of Cosmid DNA and Transformation of the Fungus Magnaporthe grisea

Cosmid DNA from the AAR1 transposon tagged cosmid clone was prepared
using QIAGEN Plasmid Maxi Kit (QIAGEN), and digested by PI-PspI (New England
Biolabs, Inc.). Fungal electro-transformation was performed essentially as described
(Wu et al. (1997) MPMI 10: 700 - 708). Briefly, M. grisea strain Guy 11 was grown
in complete liquid media (Talbot et al. (1993) Plant Cell 5: 1575 - 1590 (PMID:
8312740)) shaking at 120 rpm for 3 days at 25°C in the dark. Mycelia was harvested
and washed with sterile H2O and digested with 4 mg/ml beta-glucanase (InterSpex)
for 4-6 hours to generate protoplasts. Protoplasts were collected by centrifugation and
resuspended in 20% sucrose at the concentration of 2x10^8 protoplasts/ml. 50ul
protoplast suspension was mixed with 10-20ug of the cosmid DNA and pulsed using
Gene Pulser II (BioRad) set with the following parameters: resistance 200 ohm,
capacitance 25uF, voltage 0.6kV. Transformed protoplasts were regenerated in
complete agar media (CM, Talbot et al. (1993) Plant Cell 5: 1575 - 1590 (PMID:
8312740)) with the addition of 20% sucrose for one day, then overlayed with CM
agar media containing hygromycin B (250ug/ml) to select transformants.
Transformants were screened for homologous recombination events in the target gene
by PCR (Hamer et al. (2001) Proc Natl Acad Sci USA 98: 5110 – 15 (PMID:
11296265)). Two independent strains were identified for AAR1 and are hereby
referred to as KO1-1 and KO1-11, respectively. For HCS1, two independent strains
were also identified and are hereby referred to as HCS1 KO1-1 and KO1-2,
respectively.

Example 6
Effect of AAR1 Transposon Insertion on Magnaporthe pathogenicity

The target fungal strains, AAR1 KO1-1 and KO1-11, obtained in Example 5
and the wild type strain, Guy11, were subjected to a pathogenicity assay to observe
infection over a 1-week period. Rice infection assays were performed using Indian
rice cultivar CO39 essentially as described in Valent et al. ((1991) Genetics 127: 87 -
101 (PMID: 2016048). All three strains were grown for spore production on complete agar media. Spores were harvested and the concentration of spores adjusted for whole plant inoculations. Two-week-old seedlings of cultivar CO39 were sprayed with 12 ml of conidial suspension (5 x 10^4 conidia per ml in 0.01% Tween-20 (Polyoxyethylene sorbitan monolaureate) solution). The inoculated plants were incubated in a dew chamber at 27°C in the dark for 36 hours, and transferred to a growth chamber (27°C 12 hours/21°C 12 hours 70% humidity) for an additional 5.5 days. Leaf samples were taken at 3, 5, and 7 days post-inoculation and examined for signs of successful infection (i.e. lesions). Figure 2 shows the effects of AAR1 gene disruption on Magnaporthe infection at five days post-inoculation.

Example 7

Verification of AAR1 Gene Function by Analysis of Nutritional Requirements

The fungal strains, KO1-1 and KO1-11, containing the AAR1 disrupted gene obtained in Example 5 were analyzed for their nutritional requirement for lysine using the PM5 phenotype microarray from Biolog, Inc. (Hayward, CA). The PM5 plate tests for the auxotrophic requirement for 94 different metabolites. The inoculating fluid consists of 0.05% Phytagel, 0.03% Pluronic F68, 1% glucose, 23.5 mM NaNO₃, 6.7 mM KCl, 3.5 mM Na₂SO₄, 11 mM KH₂PO₄, 0.01% p-iodonitrotetrazolium violet, 0.1 mM MgCl₂, 1.0 mM CaCl₂ and trace elements. Final concentrations of trace elements are: 7.6 μM ZnCl₂, 2.5 μM MnCl₂·4H₂O, 1.8 μM FeCl₂·4H₂O, 0.71 μM CoCl₂·6H₂O, 0.64 μM CuCl₂·2H₂O, 0.62 μM Na₂MoO₄, 18 μM H₃BO₃. pH adjusted to 6.0 with NaOH. Spores for each strain were harvested into the inoculating fluid. The spore concentrations were adjusted to 2 x 10⁵ spores/ml. 100 μl of spore suspension were deposited into each well of the microtiter plates. The plates were incubated at 25°C for 7 days. Optical density (OD) measurements at 490 nm and 750 nm were taken daily. The OD₄₉₀ measures the extent of tetrazolium dye reduction and the level of growth, and OD₇₅₀ measures growth only. Turbidity = OD₄₉₀ + OD₇₅₀. Data confirming the annotated gene function is presented as a graph of Turbidity vs. Time showing both the mutant fungi and the wild-type control in the absence (Figure 3A) and presence (Figure 3B) of L-lysine.
Example 8

Effect of HCS1 Transposon Insertion on *Magnaporthe* pathogenicity

The target fungal strains, HSC1 KO1-1 and KO1-2, obtained in Example 5 and the wild type strain, Guy11, were subjected to a pathogenicity assay to observe infection over a 1-week period. Rice infection assays were performed using Indian rice cultivar CO39 essentially as described in Valent et al. ((1991) Genetics 127: 87-101 (PMID: 2016048)). All three strains were grown for spore production on complete agar media. Spores were harvested and the concentration of spores adjusted for whole plant inoculations. Two-week-old seedlings of cultivar CO39 were sprayed with 12 ml of conidial suspension (5 x 10^4 conidia per ml in 0.01% Tween-20 (Polyoxyethylene sorbitan monolaureate) solution). The inoculated plants were incubated in a dew chamber at 27°C in the dark for 36 hours, and transferred to a growth chamber (27°C 12 hours/21°C 12 hours 70% humidity) for an additional 5.5 days. Leaf samples were taken at 3, 5, and 7 days post-inoculation and examined for signs of successful infection (*i.e.* lesions). Figure 5 shows the effects of HCS1 gene disruption on *Magnaporthe* infection at five days post-inoculation.

Example 9

Verification of HCS1 Gene Function by Analysis of Nutritional Requirements

The fungal strains, KO1-1 and KO1-2, containing the HCS1 disrupted gene obtained in Example 5 were analyzed for their nutritional requirement for lysine using the PM5 phenotype microarray from Biolog, Inc. (Hayward, CA). The PM5 plate tests for the auxotrophic requirement for 94 different metabolites. The inoculating fluid consists of 0.05% Phytogel, 0.03% Phoronic F68, 1% glucose, 23.5mM NaNO₃, 6.7mM KCl, 3.5mM Na₂SO₄, 11mM KH₂PO₄, 0.01% *p*-iodonitrotetrazolium violet, 0.1mM MgCl₂, 1.0mM CaCl₂ and trace elements. Final concentrations of trace elements are: 7.6μM ZnCl₂, 2.5μM MnCl₂·4H₂O, 1.8μM FeCl₂·4H₂O, 0.71μM CoCl₂·6H₂O, 0.64μM CuCl₂·2H₂O, 0.62μM Na₂MoO₄, 18μM H₃BO₃. pH adjusted to 6.0 with NaOH. Spores for each strain were harvested into the inoculating fluid. The spore concentrations were adjusted to 2 x 10⁵ spores/ml. 100μl of spore suspension were deposited into each well of the microtiter plates. The plates were incubated at
25°C for 7 days. Optical density (OD) measurements at 490nm and 750nm were taken daily. The OD_{490} measures the extent of tetrazolium dye reduction and the level of growth, and OD_{750} measures growth only. Turbidity = OD_{490} + OD_{750}. Data confirming the annotated gene function is presented as a graph of Turbidity vs. Time showing both the mutant fungi and the wild-type control in the absence (Figure 6A) and presence (Figure 6B) of L-lysine.

Example 10
Cloning and Expression Strategies, Extraction and Purification of α-Aminoadipate Reductase or Homocitrate Synthase protein.

The following protocol may be employed to obtain a purified α-Aminoadipate Reductase protein.

**Cloning and expression strategies:**
An AAR1 or HCS1 cDNA gene can be cloned into *E. coli* (pET vectors-Novagen), Baculovirus (Pharmingen) and Yeast (Invitrogen) expression vectors containing His/fusion protein tags. Evaluate the expression of recombinant protein by SDS-PAGE and Western blot analysis.

**Extraction:**
Extract recombinant protein from 250 ml cell pellet in 3 ml of extraction buffer
By sonicating 6 times, with 6 sec pulses at 4°C. Centrifuge extract at 15000xg for 10 min and collect supernatant. Assess biological activity of the recombinant protein by activity assay.

**Purification:**
Purify recombinant protein by Ni-NTA affinity chromatography (Qiagen).
Purification protocol: perform all steps at 4°C:
- Use 3 ml Ni-beads (Qiagen)
- Equilibrate column with the buffer
- Load protein extract
- Wash with the equilibration buffer
• Elute bound protein with 0.5 M imidazole

Example 11
Assays for Testing Binding of Test Compounds to α-Aminoadipate Reductase or Homocitrate Synthase

The following protocol may be employed to identify test compounds that bind to the α-Aminoadipate Reductase or Homocitrate Synthase protein.

• Purified full-length α-Aminoadipate Reductase or Homocitrate Synthase polypeptide with a His/fusion protein tag (Example 10) is bound to a HisGrab™ Nickel Coated Plate (Pierce, Rockford, IL) following manufacturer’s instructions.

• Buffer conditions are optimized (e.g. ionic strength or pH, Jaklitsch, W. M. and C. P. Kubicek (1990) Biochem J 269: 247 – 53 (PMID: 2115771)) for binding of radiolabeled \(^{14}\text{C}-\alpha\)-Aminoadipic acid (Sigma-Aldrich Co.) to the bound AAR1, or for binding of radiolabeled (acetyl-\(^{14}\text{C}\)-coenzyme A (Sigma-Aldrich Co.) to the bound HCS1.

• Screening of test compounds is performed by adding test compound and \(^{14}\text{C}-\alpha\)-Aminoadipic acid (Sigma-Aldrich Co.) to the wells of the HisGrab™ plate containing bound AAR1, or performed by adding test compound and (acetyl-\(^{14}\text{C}\)-coenzyme A (Sigma-Aldrich Co.) to the wells of the HisGrab™ plate containing bound HCS1.

• The wells are washed to remove excess labeled ligand and scintillation fluid (Scintiverse®, Fisher Scientific) is added to each well.

• The plates are read in a microplate scintillation counter.

• Candidate compounds are identified as wells with lower radioactivity as compared to control wells with no test compound added.

Additionally, a purified polypeptide comprising 10-50 amino acids from the *M. grisea* α-Aminoadipate Reductase or Homocitrate Synthase is screened in the same way. A polypeptide comprising 10-50 amino acids is generated by subcloning a portion of the AAR1 or HCS1 gene into a protein expression vector that adds a His-Tag when expressed (see Example 8). Oligonucleotide primers are designed to amplify a portion of the AAR1 or HCS1 gene using the polymerase chain reaction.
amplification method. The DNA fragment encoding a polypeptide of 10-50 amino acids is cloned into an expression vector, expressed in a host organism and purified as described in Example 10 above.

Test compounds that bind AAR1 or HCS1 are further tested for antibiotic activity. *M. grisea* is grown as described for spore production on oatmeal agar media (Talbot et al. (1993) Plant Cell 5: 1575 - 1590 (PMID: 8312740)). Spores are harvested into minimal media (Talbot et al. (1993) Plant Cell 5: 1575 - 1590 (PMID: 8312740)) to a concentration of 2 x 10^6 spores/ml and the culture is divided. The test compound is added to one culture to a final concentration of 20-100 μg/ml. Solvent only is added to the second culture. The plates are incubated at 25°C for seven days and optical density measurements at 590nm are taken daily. The growth curves of the solvent control sample and the test compound sample are compared. A test compound is an antibiotic candidate if the growth of the culture containing the test compound is less than the growth of the control culture.

Example 12

Assays for Testing Inhibitors or Candidates for Inhibition of α-Aminoadipate Reductase or Homocitrate Synthase Activity

The enzymatic activity of α-Aminoadipate Reductase or Homocitrate Synthase is determined in the presence and absence of candidate compounds in a suitable reaction mixture, such as described by Gray and Bhattacharjee (Gray, GS and Bhattacharjee, JK (1976) Can J Microbiol 22: 1664 - 7 (PMID: 10066)), or Jaklitsch, W. M. and C. P. Kubicek (1990) Biochem J 269: 247 – 53 (PMID: 2115771).

Candidate compounds are identified when a decrease in products or a lack of decrease in substrates is detected with the reaction proceeding in either direction.

Additionally, the enzymatic activity of a polypeptide comprising 10-50 amino acids from the *M. grisea* α-Aminoadipate Reductase or Homocitrate Synthase is determined in the presence and absence of candidate compounds in a suitable reaction mixture, such as described by Gray and Bhattacharjee (Gray, GS and Bhattacharjee, JK (1976) Can J Microbiol 22: 1664 - 7 (PMID: 10066)), or Jaklitsch, W. M. and C. P. Kubicek (1990) Biochem J 269: 247 - 53 (PMID: 2115771). A polypeptide comprising 10-50 amino acids is generated by subcloning a portion of the AAR1 or
HCS1 gene into a protein expression vector that adds a His-Tag when expressed (see Example 10). Oligonucleotide primers are designed to amplify a portion of the AAR1 or HCS1 gene using polymerase chain reaction amplification method. The DNA fragment encoding a polypeptide of 10-50 amino acids is cloned into an expression vector, expressed and purified as described in Example 10 above.

Test compounds identified as inhibitors of AAR1 or HCS1 activity are further tested for antibiotic activity. Magnaporthe grisea fungal cells are grown under standard fungal growth conditions that are well known and described in the art. M. grisea is grown as described for spore production on oatmeal agar media (Talbot et al. 1993) Plant Cell 5: 1575 - 1590 (PMID: 8312740)). Spores are harvested into minimal media (Talbot et al. (1993) Plant Cell 5: 1575 - 1590 (PMID: 8312740)) to a concentration of 2 x 10^5 spores/ml and the culture is divided. The test compound is added to one culture to a final concentration of 20-100 μg/ml. Solvent only is added to the second culture. The plates are incubated at 25°C for seven days and optical density measurements at 590nm are taken daily. The growth curves of the solvent control sample and the test compound sample are compared. A test compound is an antibiotic candidate if the growth of the culture containing the test compound is less than the growth of the control culture.

Example 13

Assays for Testing Compounds or Candidates for Compounds That Alter the Expression of an α-Aminoadipate Reductase or Homocitrate Synthase Gene

Magnaporthe grisea fungal cells are grown under standard fungal growth conditions that are well known and described in the art. Wild-type M. grisea spores are harvested from cultures grown on complete agar or oatmeal agar media after growth for 10-13 days in the light at 25°C using a moistened cotton swab. The concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium to a concentration of 2x10^5 spores per ml. 25 ml cultures are prepared to which test compounds will be added at various concentrations. A culture with no test compound present is included as a control. The cultures are incubated at 25°C for 3 days after which test compound or solvent only control is added. The cultures are incubated an additional 18 hours. Fungal
mycelia is harvested by filtration through Miracloth (CalBiochem®, La Jolla, CA), washed with water and frozen in liquid nitrogen. Total RNA is extracted with TRIZOL® Reagent using the methods provided by the manufacturer (Life Technologies, Rockville, MD). Expression is analyzed by Northern analysis of the RNA samples as described (Sambrook et al. (1989) Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory Press) using a radiolabeled fragment of the AAR1 or HCS1 gene as a probe. Test compounds resulting in a reduced level of AAR1 or HCS1 mRNA relative to the untreated control sample are identified as candidate antibiotic compounds.

Example 14

In Vivo Cell Based Assay Screening Protocol with a Fungal Strain Containing a Mutant Form of α-Aminoadipate Reductase or Homocitrate Synthase with No Activity

*Magnaporthe grisea* fungal cells containing a mutant form of the AAR1 or HCS1 gene which abolishes enzyme activity, such as a gene containing a transposon insertion (see Examples 4 and 5), are grown under standard fungal growth conditions that are well known and described in the art. *Magnaporthe grisea* spores are harvested from cultures grown on complete agar medium containing 4mM L-lysine (Sigma-Aldrich Co.) after growth for 10-13 days in the light at 25°C using a moistened cotton swab. The concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium containing 100 μM L-lysine to a concentration of 2x10^5 spores per ml.

Approximately 4x10^4 spores are added to each well of 96-well plates to which a test compound is added (at varying concentrations). The total volume in each well is 200μl. Wells with no test compound present (growth control), and wells without cells are included as controls (negative control). The plates are incubated at 25°C for seven days and optical density measurements at 590nm are taken daily. Wild type cells are screened under the same conditions. The effect of each compound on the mutant and wild-type fungal strains is measured against the growth control and the percent of inhibition is calculated as the OD₅₉₀ (fungal strain plus test compound) / OD₅₉₀ (growth control) x 100. The percent of growth inhibition as a result of a test
compound on a fungal strain and that on the wild type cells are compared. Compounds that show differential growth inhibition between the mutant and the wild type are identified as potential antifungal compounds. Similar protocols may be found in Kirsch and DiDomenico ((1994) Biotechnology 26: 177 - 221 (PMID: 7749303)).

Example 15

*In Vivo* Cell Based Assay Screening Protocol with a Fungal Strain Containing a Mutant Form of α-Aminoadipate Reductase or Homocitrate Synthase with Reduced Activity

*Magnaporthe grisea* fungal cells containing a mutant form of the AAR1 or HCS1 gene, such as a promoter truncation that reduces expression, are grown under standard fungal growth conditions that are well known and described in the art. A promoter truncation is made by deleting a portion of the promoter upstream of the transcription start site using standard molecular biology techniques that are well known and described in the art (Sambrook *et al.* (1989) *Molecular Cloning, a Laboratory Manual*, Cold Spring Harbor Laboratory Press). *Magnaporthe grisea* spores are harvested from cultures grown on complete agar medium containing 4mM L-lysine (Sigma-Aldrich Co.) after growth for 10-13 days in the light at 25°C using a moistened cotton swab. The concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium to a concentration of 2x10⁵ spores per ml. Approximately 4x10⁴ spores are added to each well of 96-well plates to which a test compound is added (at varying concentrations). The total volume in each well is 200µl. Wells with no test compound present (growth control), and wells without cells are included as controls (negative control). The plates are incubated at 25°C for seven days and optical density measurements at 590nm are taken daily. Wild type cells are screened under the same conditions. The effect of each compound on the mutant and wild-type fungal strains is measured against the growth control and the percent of inhibition is calculated as the OD₅₉₀ (fungal strain plus test compound) / OD₅₉₀ (growth control) x 100. The percent of growth inhibition as a result of a test compound on a fungal strain and that on the wild-type cells are compared. Compounds that show differential growth inhibition
between the mutant and the wild type are identified as potential antifungal
compounds. Similar protocols may be found in Kirsch and DiDomenico ((1994)
Biotechnology 26: 177 - 221 (PMID: 7749303)).

Example 16

*In Vivo* Cell Based Assay Screening Protocol with a Fungal Strain Containing a
Mutant Form of a Lysine Biosynthetic Gene with No Activity

*Magnaporthe grisea* fungal cells containing a mutant form of a gene in the
lysine biosynthetic pathway (*e.g.* HCS1 (E.C. 4.1.3.21)) are grown under standard
fungal growth conditions that are well known and described in the art. *Magnaporthe
grisea* spores are harvested from cultures grown on complete agar medium containing
4mM L-lysine (Sigma-Aldrich Co.) after growth for 10-13 days in the light at 25°C
using a moistened cotton swab. The concentration of spores is determined using a
hemacytometer and spore suspensions are prepared in a minimal growth medium
containing 100 μM L-lysine to a concentration of 2x10^5 spores per ml.

Approximately 4x10^4 spores or cells are harvested and added to each well of 96-well
plates to which growth media is added in addition to an amount of test compound (at
varying concentrations). The total volume in each well is 200μl. Wells with no test
compound present, and wells without cells are included as controls. The plates are
incubated at 25°C for seven days and optical density measurements at 590nm are
taken daily. Wild type cells are screened under the same conditions. The effect of
each compound on the mutant and wild-type fungal strains is measured against the
growth control and the percent of inhibition is calculated as the OD_{590} (fungal strain
plus test compound) / OD_{590} (growth control) x 100. The percent of growth inhibition
as a result of a test compound on a fungal strain and that on the wild type cells are
compared. Compounds that show differential growth inhibition between the mutant
and the wild-type are identified as potential antifungal compounds. Similar protocols
may be found in Kirsch and DiDomenico ((1994) Biotechnology 26: 177 - 221
(PMID: 7749303)).
In Vivo Cell Based Assay Screening Protocol with a Fungal Strain Containing a Mutant Form of a Lysine Biosynthetic Gene with Reduced Activity

*Magnaporthe grisea* fungal cells containing a mutant form of a gene in the lysine biosynthetic pathway (e.g. HCS1 (E.C. 4.1.3.21)), such as a promoter truncation that reduces expression, are grown under standard fungal growth conditions that are well known and described in the art. A promoter truncation is made by deleting a portion of the promoter upstream of the transcription start site using standard molecular biology techniques that are well known and described in the art (Sambrook *et al.* (1989) *Molecular Cloning, a Laboratory Manual*, Cold Spring Harbor Laboratory Press). *Magnaporthe grisea* fungal cells containing a mutant form of are grown under standard fungal growth conditions that are well known and described in the art. *Magnaporthe grisea* spores are harvested from cultures grown on complete agar medium containing 4mM L-lysine (Sigma-Aldrich Co.) after growth for 10-13 days in the light at 25°C using a moistened cotton swab. The concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium to a concentration of 2x10^5 spores per ml. Approximately 4x10^4 spores or cells are harvested and added to each well of 96-well plates to which growth media is added in addition to an amount of test compound (at varying concentrations). The total volume in each well is 200μl. Wells with no test compound present, and wells without cells are included as controls. The plates are incubated at 25°C for seven days and optical density measurements at 590nm are taken daily. Wild type cells are screened under the same conditions. The effect of each compound on the mutant and wild-type fungal strains is measured against the growth control and the percent of inhibition is calculated as the OD_{590} (fungal strain plus test compound) / OD_{590} (growth control) x 100. The percent of growth inhibition as a result of a test compound on a fungal strain and that on the wild type cells are compared. Compounds that show differential growth inhibition between the mutant and the wild type are identified as potential antifungal compounds. Similar protocols may be found in Kirsch and DiDomenico ((1994) Biotechnology 26: 177 - 221 (PMID: 7749303)).
Example 18

*In Vivo* Cell Based Assay Screening Protocol with a Fungal Strain Containing a Fungal AAR1 and a Second Fungal Strain Containing a Heterologous AAR1 Gene

Wild-type *Magnaporthe grisea* fungal cells and *M. grisea* fungal cells lacking a functional AAR1 gene and containing an AAR1 gene from *Penicillium chrysogenum* (Genbank accession Y13967, 56% sequence identity) are grown under standard fungal growth conditions that are well known and described in the art. An *M. grisea* strain carrying a heterologous AAR1 gene is made as follows:

- An *M. grisea* strain is made with a nonfunctional AAR1 gene, such as one containing a transposon insertion in the native gene (see Examples 4 and 5).
- A construct containing a heterologous AAR1 gene is made by cloning the AAR1 gene from *Penicillium chrysogenum* into a fungal expression vector containing a *trpC* promoter and terminator (e.g. pCB1003, Carroll et al. (1994) Fungal Gen News Lett 41: 22) using standard molecular biology techniques that are well known and described in the art (Sambrook et al. (1989) *Molecular Cloning, a Laboratory Manual*, Cold Spring Harbor Laboratory Press).
- The said construct is used to transform the *M. grisea* strain lacking a functional AAR1 gene (see Example 5). Transformants are selected on minimal agar medium lacking L-lysine. Only transformants carrying a functional AAR1 gene will grow.

Wild-type strains of *Magnaporthe grisea* and strains containing a heterologous form of AAR1 are grown under standard fungal growth conditions that are well known and described in the art. *Magnaporthe grisea* spores are harvested from cultures grown on complete agar medium after growth for 10-13 days in the light at 25°C using a moistened cotton swab. The concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium to a concentration of 2x10^5 spores per ml. Approximately 4x10^4 spores or cells are harvested and added to each well of 96-well plates to which growth media is added in addition to an amount of test compound (at varying concentrations). The total volume in each well is 200μl. Wells with no test compound present, and wells without cells are included as controls. The plates are incubated at 25°C for seven days and optical density measurements at 590nm are taken daily. The effect of each compound on the
wild-type and heterologous fungal strains is measured against the growth control and the percent of inhibition is calculated as the OD\textsubscript{590} (fungal strain plus test compound) / OD\textsubscript{590} (growth control) x 100. The percent of growth inhibition as a result of a test compound on the wild-type and heterologous fungal strains are compared.

Compounds that show differential growth inhibition between the wild-type and heterologous strains are identified as potential antifungal compounds with specificity to the native or heterologous AAR1 gene products. Similar protocols may be found in Kirsch and DiDomenico ((1994) Biotechnology 26: 177 - 221 (PMID: 7749303)).

Example 19

\textit{In Vivo} Cell Based Assay Screening Protocol with a Fungal Strain Containing a Fungal HCS1 and a Second Fungal Strain Containing a Heterologous HCS1 Gene

Wild-type \textit{Magnaporthe grisea} fungal cells and \textit{M. grisea} fungal cells lacking a functional HCS1 gene and containing a HCS1 gene from \textit{Thermus aquaticus} (Genbank accession O87198, 56% sequence identity) are grown under standard fungal growth conditions that are well known and described in the art. An \textit{M. grisea} strain carrying a heterologous HCS1 gene is made as follows:

- An \textit{M. grisea} strain is made with a nonfunctional HCS1 gene, such as one containing a transposon insertion in the native gene (see Examples 4 and 5).
- A construct containing a heterologous HCS1 gene is made by cloning the HCS1 gene from \textit{Thermus aquaticus} into a fungal expression vector containing a \textit{trpC} promoter and terminator (\textit{e.g.} pcB1003, Carroll et al. (1994) Fungal Gen News Lett 41: 22) using standard molecular biology techniques that are well known and described in the art (Sambrook et al. (1989) \textit{Molecular Cloning, a Laboratory Manual}, Cold Spring Harbor Laboratory Press).
- The said construct is used to transform the \textit{M. grisea} strain lacking a functional HCS1 gene (see Example 5). Transformants are selected on minimal agar medium lacking L-lysine. Only transformants carrying a functional HCS1 gene will grow.

Wild-type strains of \textit{Magnaporthe grisea} and strains containing a heterologous form of HCS1 are grown under standard fungal growth conditions that are well known and described in the art. \textit{Magnaporthe grisea} spores are harvested from
cultures grown on complete agar medium after growth for 10-13 days in the light at 25°C using a moistened cotton swab. The concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium to a concentration of 2x10⁵ spores per ml. Approximately 4x10⁴ spores or cells are harvested and added to each well of 96-well plates to which growth media is added in addition to an amount of test compound (at varying concentrations). The total volume in each well is 200μl. Wells with no test compound present, and wells without cells are included as controls. The plates are incubated at 25°C for seven days and optical density measurements at 590nm are taken daily. The effect of each compound on the wild-type and heterologous fungal strains is measured against the growth control and the percent of inhibition is calculated as the OD₅₉₀ (fungal strain plus test compound) / OD₅₉₀ (growth control) x 100. The percent of growth inhibition as a result of a test compound on the wild-type and heterologous fungal strains are compared. Compounds that show differential growth inhibition between the wild-type and heterologous strains are identified as potential antifungal compounds with specificity to the native or heterologous HCS1 gene products. Similar protocols may be found in Kirsch and DiDomenico ((1994) Biotechnology 26: 177 - 221 (PMID: 7749303)).

Example 20
Pathway Specific In Vivo Assay Screening Protocol

Magnaporthe grisea fungal cells are grown under standard fungal growth conditions that are well known and described in the art. Wild-type M. grisea spores are harvested from cultures grown on oatmeal agar media after growth for 10-13 days in the light at 25°C using a moistened cotton swab. The concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium and a minimal growth medium containing 4mM L-lysine (Sigma-Aldrich Co.) to a concentration of 2x10⁵ spores per ml. The minimal growth media contains carbon, nitrogen, phosphate, and sulfate sources, and magnesium, calcium, and trace elements (for example, see inoculating fluid in Example 7). Spore suspensions are added to each well of a 96-well microtiter plate (approximately 4x10⁴ spores/well). For each well containing a spore suspension in minimal media, an additional well is present containing a spore suspension in minimal medium.
containing 4mM L-lysine. Test compounds are added to wells containing spores in minimal media and minimal media containing L-lysine. The total volume in each well is 200μl. Both minimal media and L-lysine containing media wells with no test compound are provided as controls. The plates are incubated at 25°C for seven days and optical density measurements at 590nm are taken daily. A compound is identified as a candidate for an antibiotic acting against the lysine biosynthetic pathway when the observed growth in the well containing minimal media is less than the observed growth in the well containing L-lysine as a result of the addition of the test compound. Similar protocols may be found in Kirsch and DiDomenico ((1994) Biotechnology 26: 177 - 221 (PMID: 7749303)).

While the foregoing describes certain embodiments of the invention, it will be understood by those skilled in the art that variations and modifications may be made and still fall within the scope of the invention. The foregoing examples are intended to exemplify various specific embodiments of the invention and do not limit its scope in any manner.
SEQUENCE LISTING

<110>  Tanzer, Matthew M
       Shuster, Jeffrey R
       Hamer, Lisbeth
       Adachi, Kiichi
       DeZwaan, Todd M
       Lo, Sze Chung C
       Montenegro-Chamorro, Maria V
       Frank, Sheryl A
       Darveau, Blaise A
       Mahanty, Sanjoy K
       Heisinger, Ryan W
       Skalchunes, Amy R
       Pan, Huaqin
       Tarpey, Rex

<120>  METHODS FOR THE IDENTIFICATION OF INHIBITORS OF
       ALPHA-AMINOADIPATE REDUCTASE AND HOMOCITRATE SYNTHASE AS ANTIBIOTICS

<130>   2122PCT

<160>   6

<170>   PatentIn version 3.1

<210>   1
<211>   3567
<212>   DNA
Magnaporthe grisea

<213> 1
atggcgctac agctccccga ccacaacggct gcacctcgact ggtcttggtca cgctggccgc 60
atccatgaga ttcttgccac tatgccccag aagcacccgg agcggggtggt cggatcagag 120
acacagctct cccgagccac ggaaagggata tttaacctaa acacagcttt tggcgcctca 180
aatgtcttgt gcgcactact acatgtacgt ggagtcctta atggcagatgt gcgtcatgatc 240
tgggccgata gctcagttga cctggtggtc agcatctagg gtgtctcttg tcgcggagct 300
acatcctgt gcctctgacc attatacacc ctctctcgtc acagctatat cctcgaaga 360
tccgccccga ccgcccttgg atcaacgtcc gcgcacccaa acggccagcc acggcgcggc cccgttgcc 420
cccctgctgc cgcctcagcct gctgctcgggt ggagagatca acggcgctga tgttttggcc 480
agctgcagcc gcacgcctcct ctcacccgct gcagacattg agttgcagcc gcacgccac 540
ccacactata gctctcgctgctg gctgctcggc gacccctgcgg agcagatatt ctctccgcca 600
tacctctgg gcgcgcgcct actgttggtcg tcaagagagca atttgtgcaac gcagcttcta 660
gcgagcttgt tcaagcagctt tgaacccaca gtacacccac tgaacgcgggc catgggtcag 720
ccttccacac ttctctcggg tatcgccgac gacccctgtcc agcagatatt ctctccgcca 780
cggatctgtg ggcgcgcct actgttggtcg tcaagagagca atttgtgcaac gcagcttcta 840
gcgagcttgt tcaagcagctt tgaacccaca gtacacccac tgaacgcgggc catgggtcag 900
atcttagtcg gcgcgcgtac gcagacttc tctgctcggc aaacagcctc ctctctgcgg 960
gctgctgctg cgcgcgcct actgttggtcg tcaagagagca atttgtgcaac gcagcttcta 1020
gttcactgt gcgcgcctgag tctgctgctg cggccgaaa ctggtgaact 1080
gggcgtgcag cgccggcgag tctgtctagc tctgctgctg cggccgaaa ctggtgaact 1140
gggcgtgcag cgccggcgag tctgtctagc tctgctgctg cggccgaaa ctggtgaact 1200
gggcgtgcag cgccggcgag tctgtctagc tctgctgctg cggccgaaa ctggtgaact 1260
gggcgtgcag cgccggcgag tctgtctagc tctgctgctg cggccgaaa ctggtgaact 1320
gggcgtgcag cgccggcgag tctgtctagc tctgctgctg cggccgaaa ctggtgaact 1380
gggcgtgcag cgccggcgag tctgtctagc tctgctgctg cggccgaaa ctggtgaact 1440
gggcgtgcag cgccggcgag tctgtctagc tctgctgctg cggccgaaa ctggtgaact 1500
gggcgtgcag cgccggcgag tctgtctagc tctgctgctg cggccgaaa ctggtgaact 1560
agggacaaga acgaggagcc gaagctgggtc agctacgattg tgcctgagct caagcaatgg
1620
ccccaatggc tcaagcttca tggctacagq gatgctgaaq acgatgaggg caagcaatt
1680
ggagcaacca aggtataactt caagaggtat cgtctgaatgc aggctgagct tgcctgacct
1740
cctcaagtcaat ggtggcgccag ctaagccggtct cctagcattct cctattgctca ttgagaagct
1800
ccattaacc ccaacgcggaa ggttgaccaag cccatctac ctttctccoga tatgcccag
1860
caaaacgcc agctctcaag cagaggagt tgcagagctt gcagagctt cagagagct
1920
gtgctgttg ccaccaggttg gcggcggttg atccacggtc ctgaagaaaa gtcgatcgg
1980
cccgataacc actctcttgga cctctggcgt cagagtattc tggcaacacga aatgctgttc
2040
gcgctgacga acgagatggg tgctaatgtgg ctctacaaca ccttctacga gaaccccaacg
2100
cctgggggcat tcagcttctca gattgcaacag catcttgagg cagccaatga tgctagcacc
2160
agcccaagctc aggtgaggg acaactctat cccaaagcggc gctgatgctt ctgttaagaaa
2220
cctccagctc cctcaagac acagatccgc tgcgtgaccc cggctgctac cagccatacc
2280
acctttctga ctggtgcagaa gggcttccttg ggtggtcttttg tgatctgccag tatcctcgag
2340
agggagcggc gcagctggaa gtcctagcga cagcttgccgt gcagagccac aaaaacgcggc
2400
acagacggtc tgtgaggggc actacagggc taoctgtatcc ggcgcagacac gtgggtcctgg
2460
cgccttcctc gcttctttcg tgtctactgg aagccgcaac ttggtatatg tcgcgcaca
2520
tggggagggc tgtccgcaacg gttggagctg cttatccccaa aacggctgcag agtcctactgg
2580
gtgccgctct gcgcagactc gctggcggcc gcagctcagat cgacaatcga gccagtccgg
2640
cctgcaagcc aggcaacggc aagttgttct accttctctga gctcaactag ctgctctggac
2700
acgacgactct atgtcagatt gtcggagggc caactgacga cggcgaaggg cgccgctcccc
2760
ggtgtgacgc acctggaaggg cagtgccacact ggttggctggta agggtaagcg ccaacacag
2820
tgatctcgag aagcagctgt gaggagggcg ggcgcagcgc gccagctgcag tccggctgctc
2880
agggcagact acattctggg agatcttcag tcgggatgtt ccaacccaga cgaccttccc
2940
attcgctttcc tcaagggccgt tattcogctg ggcagagggc cccggcatatt caatactgct
3000
aattgctgac ccgcaadaca cttgctgctg tgggtctgtcg cggctggttct ccaacctgta
3060
ccccagccgg gtiaagggcg tgtccagctgc gtcacgattta cggcagaccc gcggcgctggg
3120
atgagagatg atctcctggtt gttggaagct ctaagctacaag gttggccggag ggtgcccatt
3180
gattcagagtc aggagagcttg gcagcaggtac gttctgtgagg gcgcgggttg gcagacgcag
3240
cagggacgc acgctgactg accttcttcac cccctctgta tctegggact gcggcagcag
3300
actaaggcag ctgagcttga ggaccaaaac gcttgccgag tcccataagg ccgtgctgag 3360
gctgacctgg ggctgacaga gacgagctgg tcaagcatcg gcagggagga ctgcaaggag 3420
tactcggcct acctagccat gatcaagttt gtccccctggc ctaagctgag ggccaggtct 3480
ttgccctgagg tcagcatcag cagggagcag gtggctgtctg atggtgcagg cttgcggtag 3540
cgctggggtg cgggctgaggg acagtga 3567

<210> 2
<211> 7586
<212> DNA
<213> Magnaporthe grisea

<400> 2
catacagagt cagtttagga agccctggctc ttggagagct cccgagccaa atttggcccag 60
aaattaagca ttcatgccaa gacgctgctc cgtatgtcag aataccgaaat gtcatttgtg 120
atatatttttt ttatatattttc gcaggtcatct aattgacatt tggaaagtcc agttccaccgctg 180
accagagta ctcacctotc ttttttttta gcaagcatct tgggtgcttg cggtgctttt 240
gttgctgttg atgtctgttaa aagatctcaat cgcacccgag ggccgtttaat aagcctata 300
aaccttgcaaa aagctaggg tgtcactacc agtcaacgca tacacaccttg cgcagtagta 360
cccgaccaat tgtcccccatt caagataaat ctcacaccatg ggcacatcag tccccgaccct 420
aacgggtcgac ctcgactgtgt tgtgctgtctg ggccgcctatg cacagatctct tggccactta 480
tgcccaagaa cccccgagc ggtggtgtgtgt gatcgagaca gatctctcag ggccacccgg 540
aaggtatatgt atctacaaac agatctttgga ggcggctccaa atctctgggcg acatccctaca 600
tgatgtggta gttcactaatg cgcaggtgtgt gatgatctgg ggccataggt cagttaacct 660
ggtggtcgac atcatggggt ttotgtgaag atgtcatcttc cccccctattg aacgctgccg 720
attccccgcc ttgttctagg cagcatcgtg tctccgcagag aacggaacgt cagcatcgtg 780
caaaaacctt ctcagggcgg cggagttaca ttctggtcttc ttgaccatt atacccgcctta 840
tctctgcagc agatctaatct cgaagttacc gcggggacgct ccccttctcaat aatccgcgctg 900
gccacggagc aggcccggccc gtggcccttg ctcgctgcac ccgggttcaga cggaggctg 960
aagctgaaag ggaggttcgg gcgtcactagc atcggcgacgt atggccacct ctcgggtgga 1020
gagatcaacg gccgtctagt gttgcccagc gtgcgcggcga aggcatacct acgcgcctgca 1080
gacattgagg tccgaacccga ctgaaaccac aacaatagct tacgctcagg ctgcgaaggc 1140
cggccataagg gcctgctcttg tcgacactac agcottggcga agtatatttg atggatgccc 1200
gagaagtctgc gcatgagccga agagacccgc ttcacactgc tccgctggtat cggcagacac 1260
cctgtgcagc gagatatctt cacgctctgt ctcctgcggcg cgcgcttacct gttggccgtcc 1320
aaggagaata ttgcaacacga gcgtctagcga gacgtcttca gacgtcttga agggtttaga acaacacagt 1380
acaacaactga ccggccgcaat cggctcagat ttgctcgccg cgcgactac gcgcagcttc 1440
gcctgaattt cccgctgcttt gttgctgacga cccggagacct cccgacaggt 1500
gctgacagtgc ggcaacagcttg acatctgtgta accatgtaag ggacgacttga gacagacga 1560
gctgtcaagtc actcaagatg ccggaacccgc gctcagaccc ccgaccaaccttt gggagagattg 1620
gggaaggaca caatccctgg cggagctggc atgggaaacgc ttggatctttt gttggctcaac 1680
cgggaagaata ggcaagagctt tttggtatttc gggaagttgg ggagatgatat ccgctgcgac 1740
gctgggtctgg ctcgggtcta ccggggcagc ccgcgtcttga agcaacaacga gttctctgatg 1800
aactggttgcgttgattc aacggagaatt ggggcaacca aacgagcacc cgggtgccccc aaccaaggat 1860
gcggcagatg ccaggtcacta ccggccctct ctcgagagcc tgcagacgcc aggtgcaccc 1920
gggaagtttt gttgatctgg ccgatctggaa tggcaagatctg tggcagacga tcaagtcgaa 1980
atcaggggct tcagagtggta actcaacgcag atttgacacca acctgagtcga gctcctcttc 2040
atcaggagct gcagacgctg tgcgcaaggg gacaaggaacg agagccggagagctgtgctcg 2100	
taaggttgcc gctagctcaag caaatggccc caaagttgtca acgttctacttg ctcagaggt 2160
gctgaagagct atggggcgac gcgaattgtga gcaaccaaggg tatacttctaa gagtattcg 2220
cgtatcagg gcctgctctcg acgatcctct acgatcagagtt tgcagaccc acgcgcctgg 2280
agcatcttca ttgctctgga gacgtctgca ttaataccca aagggcaggt tgacaagccc 2340
aatctacctt ttcggctatag tgcggaccaaa acgcgcgaag cttaagcaagc ggagattgag 2400
cgttgggagct ttctgacagg gccctgagcgct gctgttgcga ccaaggctgggc tgcgttggatc 2460
cagggtctag aacgaagatgc gatcgcggcc cttacaacggt tttttgaccc cgggctcgcac 2520
agttctctgg cacagcaaat gccgctcagac gcggcgaagc agatggtggtc taatggatct 2580
atcaacacc tttcacgagaa cccccgccttt ggggcattgca gcttctagat tgacaacgat 2640
cctggagcag ccaatgagtc tagcaccagc caagtccagg atggagcaca ctcgtcatgctgc 2700
aagacgtccttg atgtctcgtg taaaaaccttt ccagctcctct acaagagcagc agatccgtgg 2760
tcgatccgga cgctatcgcag acctaccctc ttcttgactg gcgcaaccggt tttcttggtt 2820
gccttttttg a cctgcgatat cctgcagagg acgagccgac agctgaagct cactgcacac 2880
gttggttcca aggacaaaaa acggcggcaca gaggctcttgta cgcggtctact acagggctac 2940
ggtatctgggc ggcagctagt ggctgggggc ctttctctgcg tagtggggtta cctagccaag 3000
cgcacaatgc gtattgacatc gcccacatgg gagcgctctgt gcgaacgagt ggacgtaggt 3060
atccacaacg gtgcgcagagt ccactggggtg gcggctgtggc aagacagctg ggccgcacac 3120
gtgcacatca gaatcgcagc catgcggctgc tgcacagggg gcacgcaaga ctttactcct 3180
tttgctctagt caactagctg ctttgacact gagaactagt tcgactgtgc ggacggcaga 3240
tgtagccacc gcacagcccgc gcctcccggag tctgaagcac tgcgaagcac tgcacctggc 3300
ctgcggctca aaccacactc acctccctcag ttagggaacc tgggctctggg 3360
agagctcccg gcggaaattgg ccccaagaaa taagcatcga tgcgaagcag gcgtccccag 3420
tgtgcgaata ccaatgcaga tttgtgtcata atttttttta cattctgacg ggatctaat 3480
agacctttaa aagtcgagtc aggctcaccag gcagttactca ctttcttttt tcctccagca 3540
gccattgtgg gggtctgtggc ctttcttttt tcgtagtggt ctgtgaaaga ttcactcag 3600
gecagggcga atttxtaatgc cattataact tgtgcacaaag cttagggttca cataccagtc 3660
aacgcataca cactggccga gtatgtaccc gcgaatggtgc ccccatccag ataaaatcgc 3720
accatgggcc aacgcataca cagccccttgc gcggacatgc acctgctcgc ctacgtcggc 3780
gccacatcag aggatcttgc gcacatggtcc gagagaaccc cggagcggtt gcgctgtgatc 3840
ggagacaggt cctccggagcc accggaaagg atatattact aacaagcagat ctttggagcc 3900
tcaatagtcc tggcgaacta cctacatgat gcttggactca tcaatsggca tgtgttcatg 3960
atctgggccc atttggtcgct tggagtctct gcagttcgtt gagagttctg 4020
atctttccttc ctatgactac gcagcgagtc cccgccttggc ctttagccag actgttttctc 4080
cgagagaacc gaaacatgta catgacaaaa accatctctca ggcgtggcggga gctacatccta 4140
gtgctcttga cccatttaac ccggcatcctc gcagcgagatc atacctggagaa ctatccccgc 4200
cgagagcctctg tgtacaattcc gcgcgcgttcc gcgcagagtgc gcgcagcttttg gcccctctcg 4260
tgccccagtt catcgacagag gactgtgagtc tgaagggcaga ggttccggtc ctaagcagtag 4320
ggcagagttt cccacacttcg cttggagaga tcaaggccgcg tgaatgttttt gccagcgtgc 4380
gcggcagccc acctccacag cctgcagaca ttggctcggg accggactgc acccccacac 4440
ttaccttcac gtcaggctcg gaaggccggc ctaagggcggt gctgtgtcga cactacagct 4500
tggccagaata ttttcgattg atggccgaga cggctggcat gggccgagag acggccttcga 4560
cactgctcga gggtatccg ccagacccctg tgcagcggaga tctttccaaac gcactgttacc 4620
tggccgagccc cctactgttgct ccgcttcgaa aggataaatgc acagcgacgct ctacgcagat 4680
ggttcaagcg cttgcaacca acaagtgaacac acctgacgcg gcgcaatgggt cagatttttag 4740
tccgaggggct taccgacagct ttccctgccc tgaaacacgc ctaacctgctgc ggagtgtcgc 4800
tgacgagagc agactgccgc agtcctggtgct agctgctggccc aaacgctggac attgtaacca 4860
tgtacgagcac gcgtgagagc agccagagctc tcagctacta caagatccga aacgcctgctg 4920
cagacccgga cttttctggag aagattggca aggaccacaa cctgtgtgga actggccagttg 4980
aaaaagttcaa gctttttgtgt gtaacacggg aagatagac caagccttttct ggctatgcgc 5040
aagttgggca gatctacgtg cgctgctggctc gtcgctgctga gggctcaaca gcgcaccccg 5100
ccttgaacga cagcagacttc ctgatgaaact ggtcctgtgga taacacacaa tgggtttgag 5160
cggacaggtt gcaccacacc aaggagctgg ctgagagaaa gatctacaag ggcctcttccg 5220
acaggtgtga ccggcagaggt gacctcggag aagatattgga ttggggtcacgt gtagaatgca 5280
cggccctgagc agagctcaca gtcacacattca ggggcttcag gattgaaactc aacgcacattg 5340
acagcaacct gagtccagcc tccctcatca ggagactgcaaa gacgcttttg tcgaaggaca 5400
agaacagaga cggcaagcgtg gtcagcctag ttcgctgcgt gctcaagcga tgcccccacat 5460
gctcaagct tcatggcctac gaggatgctg aagacgtgca ggacacggaa attgggacat 5520
ccaaagtata cttcaagagg tatgctgctga tgccggtcag gcctgcgac gcttcattaag 5580
caggttggcc gacctacaag ctctcttaggt ccttcattgt cctggagaga tgtgcccattaa 5640
accccaacgag caaggttgac aacgccaaatc tacccctttccc cggatattg ggaacacccg 5700
cggagctctt cagcggagag attagagcgat gggagcttttt gacccgagctc ggcctgtcgt 5760
ttgccaccag gttggctgcgt tgtatccagg cttgcaacga aaagtcgatg gcgcacgata 5820
accaccttcttgacccctggcttgcgtcagta tttgcgcata gcgaaatgctg ctgacgtgct 5880
gcaacagcat ggtgtcaatat gcgtctataca acaccccttta cggagaaacc cagctgtgggt 5940
cattcagtct taacagttgc aacgcatccttg gacgcccaca tggattcagc accagcgcaag 6000
tcgaggagtga gcgaaacttc ttagcctaag cttggtatgag atcctttcag aacctcttcag 6060
cccatacaca gcagcgagct csgtgcgtgca tccgggctgc acaccaaatc accatcttcc 6120
tgactggccgc aacgggctttc ttgggtgctct ttttgatcgc cgatatcctgc gcagagagca 6180
gccgacagct gaagctcttc gcacaagtgcc gtgccaagga ccaaaaacgc gcgacagagc 6240
gtctgacgcg gtcaactacag ggctaoggtta tctggccgca cgagtgggctt gggccgctttt 6300
cctgcttagt ggggtgaaccta gcacagggcc aacattggatat tgcacagcc acatgaggaac 6360
gctgtgcaaa cagagtggac gtagttatcc acaaggtggc gacagttccac tgggtgcgcc 6420
gctggcagaga catgctgccc gcacacgtca ctcgacaaat gcggccagat gcgctggtgca 6480
acgagggcaca gcacaaagtgt ttcaccttctc tcagctcaca tagcgtcttgg gacactgagc 6540
actatggtca gttgtcggag aggcaactga gcacgggca gacacgggcc acgagtcctg aggctgtctg 6600
acagcctcaga agggagtgcc actggtctgg gcaggtgtta gcgcggcaac agatggatct 6660
cggagacagct gtcgagggag gcgggggcgc gcagactcttg agggctctgg tgtgtggcag 6720
gtcacatttt cggagagtttc gaggtcggtat ttgccaattac agacacatttc ctcatttcg 6780
tcactcaagg cgtgatcaca ctcgaccagcg ggcccgccat tctaaatact gtcaatgccc 6840
tgctgctcag ccacgttggtog cggttgtgtgg tggcggctgg tctcaacctc gtacctccct 6900
agggtaaatga aggtgtcaca gtcgctccag ttacggggca cccgacgcttg cggatgaacg 6960
agttcttttc gttgtgtttag ttctacgctc acaaggtggcc gcaggtgccg tatgtttcct 7020
sgaaggagga gctggacgag taaagtgtctg cgggaggggg tgctgaggege gaccaggagc 7080
agcacgcgct gtcacatttc ttcacctctc gtatctcggta cctgcccgcg acacacattgg 7140
cacatggcgc tggaggcaaa aagctgtgtcg cggctcctcag ggcgagcgc agggcttggga 7200
caggggtcga cgagacgccg gtcacctggga tggccagggga ggcgttcgga aggttctaccc 7260
gtcacatgc catgatcagc ttgtctccct ggcctagctc gggggcagag ctgggtgcttg 7320
aggtcagcat cagcagggag caggtggttcg ctatggggtgc aggcgtcggtt ggaacgtggtg 7380
gtcgccgggtgc gggacagtga acgaaaaagaa tgggtgagcgg ctagccacatc ggtatatga 7440
cgtttttttc taaaatgaatt ggtaggcttgg gcttttttaaa aggtgtcttgg ttggaatgt 7500
aaagttgatt ttcgggctca aaaaaaaaaa aaaaaacctcg agggggggggc gggtacccca 7560
ttcgcctctt aagtgagtcgt attcag
<213> Magnaporthe grisea

<400> 3

Met Ala His Gln Leu Pro Asp Pro Thr Val Asp Leu Asp Trp Ser Gly 1 5 10 15

Tyr Val Gly Ala Ile His Glu Ile Phe Ala Thr Asn Ala Gln Lys His 20 25 30

Pro Glu Arg Val Cys Val Ile Glu Thr Glu Ser Ser Glu Ala Pro Glu 35 40 45

Arg Ile Phe Thr Tyr Lys Gln Ile Phe Glu Ala Ser Asn Val Leu Ala 50 55 60

His Tyr Leu His Asp Ala Gly Val Thr Asn Gly Asp Val Val Met Ile 65 70 75 80

Trp Ala His Arg Ser Val Asp Leu Val Val Ser Ile Met Gly Val Leu 85 90 95

Ala Ala Gly Ala Thr Phe Ser Val Leu Asp Pro Leu Tyr Pro Pro Ser 100 105 110

Arg Gln Gln Ile Tyr Leu Glu Val Ser Gly Pro Thr Ala Leu Val Gln 115 120 125

Ile Ala Arg Ala Thr Asp Glu Ala Gly Pro Leu Ala Pro Leu Val Arg 130 135 140

Arg Tyr Ile Asp Glu Glu Leu Lys Leu Lys Ala Glu Val Pro Ser Leu 145 150 155 160

Arg Ile Gly Asp Asp Gly His Leu Ser Gly Gly Glu Ile Asn Gly Ala 165 170 175

Asp Val Phe Ala Ser Val Arg Gly Lys Ala Ser Ser Pro Pro Ala Asp 180 185 190

Ile Glu Val Gly Pro Asp Ser Asn Pro Thr Leu Ser Phe Thr Ser Gly 195 200 205
Ser  Glu  Gly  Arg  Pro  Lys  Gly  Val  Leu  Gly  Arg  His  Tyr  Ser  Leu  Ala
   210                                215                                220

Lys  Tyr  Phe  Arg  Trp  Met  Ala  Glu  Thr  Phe  Gly  Met  Gly  Glu  Glu  Ser
   225                                230                                235                                240

Arg  Phe  Thr  Leu  Leu  Ser  Gly  Ile  Ala  His  Asp  Pro  Val  Gln  Arg  Asp
   245                                250                                255

Ile  Phe  Thr  Pro  Leu  Tyr  Leu  Gly  Ala  Arg  Leu  Leu  Val  Pro  Ser  Lys
   260                                265                                270

Glu  Asn  Ile  Ala  His  Glu  Arg  Leu  Ala  Glu  Trp  Phe  Lys  Arg  Phe  Glu
   275                                280                                285

Pro  Thr  Val  Thr  His  Leu  Thr  Pro  Ala  Met  Gly  Gln  Ile  Leu  Val  Gly
   290                                295                                300

Gly  Ala  Thr  Ala  Gln  Phe  Pro  Ala  Leu  Lys  Thr  Ala  Tyr  Phe  Val  Gly
   305                                310                                315                                320

Asp  Val  Leu  Thr  Arg  Asp  Cys  Arg  Ser  Leu  Arg  Glu  Leu  Ala  Ala
   325                                330                                335

Asn  Val  Asp  Ile  Val  Asn  Met  Tyr  Gly  Thr  Thr  Glu  Thr  Ser  Arg  Ala
   340                                345                                350

Val  Ser  Tyr  Tyr  Lys  Ile  Pro  Asn  Arg  Ala  Ser  Asp  Pro  Asp  Phe  Leu
   355                                360                                365

Glu  Arg  Leu  Gly  Lys  Asp  Thr  Ile  Pro  Ala  Gly  Thr  Gly  Met  Glu  Asn
   370                                375                                380

Val  Gln  Leu  Leu  Val  Asn  Arg  Glu  Asp  Arg  Thr  Lys  Leu  Cys  Gly
   385                                390                                395                                400

Ile  Gly  Glu  Val  Gly  Glu  Ile  Tyr  Val  Arg  Ala  Ala  Gly  Leu  Ala  Glu
   405                                410                                415

Gly  Tyr  Lys  Gly  Asp  Pro  Ala  Leu  Asn  Glu  Gln  Lys  Phe  Leu  Met  Asn
   420                                425                                430
Trp  Phe  Val  Asp  Asn  Asn  Lys  Trp  Val  Glu  Ala  Asp  Arg  Val  His  Pro  
                      435                                         440                  445

Thr  Lys  Asp  Ala  Ala  Trp  Arg  Lys  Tyr  Tyr  Lys  Gly  Pro  Leu  Asp  Arg  
                      450                                         455                  460

Leu  Tyr  Arg  Thr  Gly  Asp  Leu  Gly  Lys  Tyr  Leu  Asp  Ser  Gly  Asp  Val  
                      465                                         470                  475                  480

Glu  Cys  Thr  Gly  Arg  Ala  Asp  Asp  Gln  Val  Lys  Ile  Arg  Gly  Phe  Arg  
                      485                                         490                  495

Ile  Glu  Leu  Asn  Asp  Ile  Asp  Ser  Asn  Leu  Ser  Gln  Ser  Ser  Leu  Ile  
                      500                                         505                  510

Arg  Asp  Cys  Lys  Thr  Leu  Val  Arg  Arg  Asp  Lys  Asn  Glu  Glu  Pro  Lys  
                      515                                         520                  525

Leu  Val  Ser  Tyr  Val  Val  Pro  Glu  Leu  Lys  Gln  Trp  Pro  Gln  Trp  Leu  
                      530                                         535                  540

Lys  Leu  His  Gly  Tyr  Glu  Ala  Glu  Asp  Asp  Glu  Gly  Thr  Gln  Ile  
                      545                                         550                  555                  560

Gly  Ala  Thr  Lys  Val  Tyr  Phe  Lys  Arg  Tyr  Arg  Met  Gln  Ala  Glu  
                      565                                         570                  575

Leu  Arg  Asp  His  Leu  Lys  Ser  Arg  Leu  Pro  Thr  Tyr  Ala  Val  Pro  Ser  
                      580                                         585                  590

Ile  Phe  Ile  Val  Leu  Glu  Lys  Leu  Pro  Leu  Asn  Pro  Asn  Gly  Lys  Val  
                      595                                         600                  605

Asp  Lys  Pro  Asn  Leu  Pro  Phe  Pro  Asp  Ile  Ala  Glu  Gln  Thr  Ala  Glu  
                      610                                         615                  620

 Ala  Ser  Ser  Glu  Glu  Ile  Glu  Arg  Trp  Glu  Ser  Leu  Thr  Glu  Thr  Glu  
                      625                                         630                  635                  640

Arg  Ala  Val  Ala  Thr  Arg  Ala  Ala  Leu  Ile  Gln  Gly  Leu  Asn  Glu  
                      645                                         650                  655

Lys  Ser  Ile  Ala  Pro  Asp  Asn  His  Phe  Phe  Asp  Leu  Gly  Gly  His  Ser  

   11
Ile Leu Ala Gln Gln Met Leu Leu Asp Val Arg Lys Gln Met Gly Ala
675 680 685

Asn Val Ser Ile Asn Thr Leu Tyr Glu Asn Pro Thr Leu Gly Ala Phe
690 695 700

Ser Leu Gln Ile Asp Lys His Leu Gly Ala Ala Asn Asp Ala Ser Thr
705 710 715 720

Ser Gln Val Glu Asp Glu Ala Asn Ser Tyr Ala Lys Ala Arg Asp Asp
725 730 735

Leu Val Lys Leu Pro Ala Ser Tyr Lys Thr Ala Asp Pro Ser Ser
740 745 750

Ile Arg Ala Ser Ser Arg Pro Thr Ile Phe Leu Thr Gly Ala Thr Gly
755 760 765

Phe Leu Gly Ala Phe Leu Ile Arg Asp Ile Leu Gln Arg Thr Ser Arg
770 775 780

Gln Leu Lys Leu Ile Ala His Val Arg Ala Lys Asp Gln Lys Ala Ala
785 790 795 800

Thr Glu Arg Leu Thr Arg Ser Leu Gln Gly Tyr Gly Ile Trp Arg Asp
805 810 815

Glu Trp Ala Gly Arg Leu Ser Cys Val Val Gly Asp Leu Ala Lys Pro
820 825 830

Gln Leu Gly Ile Asp Gln Pro Thr Trp Glu Arg Leu Ser Asn Glu Val
835 840 845

Asp Val Val Ile His Asn Gly Ala Thr Val His Trp Val Arg Arg Trp
850 855 860

Gln Asp Met Leu Ala Ala Asn Val Thr Ser Thr Ile Glu Ala Met Arg
865 870 875 880

Leu Cys Asn Glu Gly Lys Pro Lys Leu Phe Thr Phe Val Ser Ser Thr
885 890 895

12
Ser Val Leu Asp Thr Glu His Tyr Val Gln Leu Ser Glu Arg Gln Leu
900 905 910
Ser Thr Gly Gln Gly Ala Val Pro Glu Ser Asp Asp Leu Glu Gly Ser
915 920 925
Ala Thr Gly Leu Gly Thr Gly Tyr Gly Gln Thr Lys Trp Ile Ser Glu
930 935 940
Gln Leu Val Arg Glu Ala Gly Arg Arg Gly Leu Arg Gly Ser Val Val
945 950 955 960
Arg Pro Gly Tyr Ile Leu Gly Asp Phe Glu Ser Gly Cys Ser Asn Thr
965 970 975
Asp Asp Phe Leu Ile Arg Phe Leu Lys Gly Cys Ile Gln Leu Gly Thr
980 985 990
Arg Pro Arg Ile Leu Asn Thr Val Asn Ala Val Pro Val Asn His Val
995 1000 1005
Ala Arg Val Val Val Ala Ala Gly Leu Asn Pro Val Pro Val Gln
1010 1015 1020
Gly Asn Glu Gly Val His Val Val His Val Thr Gly His Pro Arg
1025 1030 1035
Leu Arg Met Asn Glu Tyr Leu Ser Leu Leu Glu Phe Tyr Gly Tyr
1040 1045 1050
Lys Val Pro Glu Val Pro Tyr Asp Ser Trp Lys Glu Glu Leu Glu
1055 1060 1065
Gln Tyr Val Ser Ala Gly Ala Gly Val Glu Arg Asp Gln Glu Gln
1070 1075 1080
His Ala Leu Leu Pro Leu Phe His Leu Cys Ile Ser Asp Leu Pro
1085 1090 1095
Ala Asn Thr Lys Ala Pro Glu Leu Glu Asp Gln Asn Ala Val Ala
1100 1105 1110
Val Leu Lys Ala Asp Ala Glu Ala Trp Thr Gly Leu Asp Glu Ser
1115
1120
1125

Ala Gly Tyr Gly Ile Gly Arg Glu Asp Val Gly Arg Tyr Leu Arg
1130
1135
1140

Tyr Leu Ala Met Ile Lys Phe Val Pro Trp Pro Thr Ser Arg Gly
1145
1150
1155

Arg Pro Leu Pro Glu Val Ser Ile Ser Thr Glu Gln Val Ala Ala
1160
1165
1170

Met Gly Ala Gly Val Gly Gly Arg Gly Gly Ala Gly Ala Gly Gln
1175
1180
1185

<210>   4

<211>  1458

<212> DNA

<213> Magnaporthe grisea

<400> 4
atgtgcctca cctgcgaccc tgcagcaagcc gctgcctccca atggcaatgc gaacggaatc 60
agcgctccca atggcaatgg aaaccacgac ggaatgacgt gtagtgacag tcgccaagca 120
caaaaacgc acgtacccagcc atcaacgggat cccatccagc cgctgctttga ctttttgctc 180
aaggtgaaca acttcaacag cattgagac accttgagag agggcgagca gttcgcctaat 240
gcctttctcg accacggcaca gaagatttgg atggcctcaag ggcttgaacga cttttggtcgc 300
gactacactg agctacaacag cccggtgtcc tcggagcagt cccacgctttga cttgcgtgcc 360
atctgcaagc tgggactccca ggccaagagtgc tctaccccaac tcaggtggcc caatggacgc 420
gccgcatcct ccggtgcttc ggcgttgctac ggtggctgaca ttgctcatcgg caacctttccg 480
ttcctctgatt agcaactgca cgcccaaggaat agaactctaca tcaaccaacac gcacgattgag 540
gtcatcaact ttgctcaagag ccaggggctccag ggtgcttgcct ttcatacctga ggacactggttc 600
cgcagcacc tggctgctccgct ccaggtgctac ccaggtgctgca cggcatccacagc gtcctggcttcc 660
cgtggcttta ttggctgctac cgctgctgctcgctgctgcc gcaggtgcctca cgacactggttc 720
aagcccccag ctggcttgcc tctgctgcttc atggagccac acctccacaa cgacactggtgc 780
tgtgccatct caaatgtttt ttgogctttg gaggccgggtg ctacccccacat cgacacgtgt 840
gtcctggtta togccgagcg taacogaaatt acccctctttg gaggtctgtat ggctcgcagt 900
attgtcggct ccaaggacat ctgctcgtgc aagtaacaagc tgcacacaagc caaggacatt 960
gaggagctttg ttgccgaagc cgttcaggtc aacatctcctt tcaataacta ctcacttgtt 1020
ttctgtgctt tcaacceacaa ggccccggtatc cattgcacag cattttcctaa gaaccctota 1080
acatatgaga ttatgaccce gactctgttc ggccatcacac gctgtgctca cttgccccagc 1140
agattgacgg gatggaagc aatcaagagc agagccagcg acgcctacacag ctcgtacagg 1200
gatgagcagtt gcacaggagtc cactgccaaag atcaagctgtt tggctgagct ctcgctcgc 1260
gctatcgcag acgccccgctc atcatccttgc acgtctccac gcagcatacaag cttggccgag 1320
cctattcagtt cctctggaag cctgtctccc aacatgacgg aggaggagaagg ccocgcctcg 1380
gcaagatgtag agcgcgctga agtcagacat ggccagccaccc cggccgccccgg cagggccaa 1440
gtgcaggtgtt ttgcagcag 1458

<210> 5
<211> DNA
<212> Magnaporthe grisea

<220>
<221> exon
<222> (130) .. (384)
<223>

<220>
<221> exon
<222> (551) .. (1041)
<223>

<220>
<221> exon
<222> (1101) .. (1349)
<223>

<220>
<221> exon
<222> (1415) .. (1459)
<223>

<220>
<221> exon
<222> (1519) .. (1572)
<223>

<220>
<221> misc_feature
<223> Connect exons 1 to 6 for coding sequence (CDS)

<400>  5
caaagcttga gctccacgc gcgttagaag tgtggatcc cccggtgtgc 60
aggaattcgg cacgagccaa gttcgcagcct cccattgagc tttactcaca aacaatccca 120
accacaaa atg tgc cca tcc tgc gag cct gag caa ggc gct gcc tcc aat 171
Met Cys Pro Ser Cys Glu Pro Glu Gln Ala Ala Ala Ser Asn
1   5

5

219
ggc aat ggc aac gcc aat ggc gcc tcc aat ggc aat gga aac cac gac
Gly Asn Ala Asn Gly Asn Gly Ala Ser Asn Gly Asn Gly Asn His Asp

16
15 20 25 30

gga atg act ggt att gag act cgc csa gca caa aac gca ggc tac cag
Gly Met Thr Gly Ile Glu Thr Arg Gln Ala Gln Asn Ala Arg Tyr Gln

35 40 45

cca tca cgg aat ccc tac cag ccc gtc ggt gac ttt ttg tcc aac gtt
Pro Ser Arg Asn Pro Tyr Gln Pro Val Gly Asp Phe Leu Ser Asn Val

50 55 60

aac aac ttc aag atc att gag agc acc ctg cga gag ggc gag cag ttc
Asn Asn Phe Lys Ile Ile Glu Ser Thr Leu Arg Glu Gly Glu Phe

65 70 75

gcc aat gcc ttc gcc gag cag gtg gcg tca ag gcc caa atc gcc caa atc gct ggc tcg gag tca ag
ttc aat gcc ttc gcc gag agc acc ctg cga gag ggc gag cag ttc
414
Ala Asn Ala Phe Phe Asp Thr

80 85

ttgctcctcag acggggcgc agcctgggct accttggtag ctgcggcggtg ttggctgtg

474

cgatgtgctc tggccgcttc ccggggcgaaa aacagacctc atagactgac tcatgttttt

534

tttacccctcc gccag gcc aag aag att gag atc gcc aag ggc tgg cgg cag gcac
Ala Lys Lys Ile Glu Ile Lys Ala Lys Ala Leu Asp Asp

586
90 95

ttt gcc gtc gcc gac tac atc gag ctc acc agc cgg gct gcc tcg gag cag
Phe Gly Val Asp Tyr Ile Glu Leu Thr Ser Pro Ala Ala Ala Ser Glu Gln

100 105 110

tcc agg ctt gcc gtc gcc atc tgg aag ctg gga ctc aag gcc aag
Ser Arg Leu Asp Cys Ala Ala Ile Cys Lys Leu Gly Leu Lys Ala Lys

115 120 125

atc ctc acc cac atg ctc cac atg gag gac gcc cgc atc gcc gtc
Ile Leu Thr His Ile Arg Cys His Met Asp Ala Arg Ile Ala Val

130 135 140 145

gag acc ggt gtt gac ggg gtc gcc gac att gtc atc gcc acc tct tcg tcc
Glu Thr Gly Val Asp Gly Val Asp Ile Val Ile Gly Thr Ser Ser Phe

150 155 160

ctc atg gag ctc ctc gc ggc aag gag atg acc tac atc acc aac aag
Leu Met Glu His Ser His Gly Lys Asp Met Thr Tyr Ile Thr Asn Thr

165 170 175

gcc att gag gtc atc aac ttc gtc aag aac aag ggc atc gag gtc cgc
Ala Ile Glu Val Ile Asn Phe Val Lys Ser Lys Gly Ile Glu Val Arg

180 185 190

ttc tca tcc gag gcc tcg ttc gcc gcc ggc aac ctg ggt gac ctg cgc
Phe Ser Glu Asp Ser Phe Arg Ser Asn Leu Val Asp Leu Leu Ser

195 200 205

atc tac tgc acc gcc aag att gtt gtc aac cgt gtc ggt att gct
Ile Tyr Ser Thr Val Asp Lys Ile Gly Val Asn Arg Val Gly Ile Ala

210 215 220 225
gat acc gtc gtt tgc gcc tcg ccc cgc cag gtc tac gaz ctg gtc aag
Asp Thr Val Gly Cys Ala Ser Pro Arg Gln Val Tyr Asp Leu Val Lys
230 235 240

acc ctg cgt ggt gtc tct tg tgtgaccaca ggttgtatga atcttgtgtct
Thr Leu Arg Gly Val Val Ser Cys
245

gcttggctgtagctacacagttgctag t gag att gag aca cac ttc cac aac
Asp Ile Glu Thr His Phe His Asn
250 255

gac act ggc tgt gcc atc tca aat gtt ttc tgc gct tgg gag gcc ggt
Asp Thr Gly Cys Ala Ile Ser Asn Ala Leu Ala Gly
260 265 270

gct acc cac atc gac acc tgt gtc atg gcc ggt atc gcc gag ctg aac gga
Ala Thr His Ile Asp Thr Cys Val Leu Gly Glu Arg Asn Gly
275 280 285

att acc cct ctt gga ggt ctg atg gct cgg atg att gtc ggc ttg aag
Ile Thr Pro Leu Gly Gly Leu Met Ala Arg Met Ile Val Gly Ser Lys
290 295 300 305

gac tac gtt ctg aag tac aag ctg cac aag ctc aag gac att gag
Asp Tyr Val Leu Ser Lys Tyr Lys Leu His Lys Leu Asp Ile Glu
310 315 320

gcg tgt ggt gcc gac gcc gtt cag gtc aac at gtaagttttg ccattccagt
Glu Leu Val Ala Asp Ala Val Gln Val Asn Ile
325 330

gcagttttca ttctgggtag gattgcaaac attttgtcct tggatgtag t cct ttc aat
Pro Phe Asn
335

aac tac atc act ggt ttc tgt gct ttc acc cac aag gttgtttccg
Asn Tyr Ile Thr Gly Phe Cys Ala Phe Thr His Lys
340 345

tcaacactg gtatctacta ttgatccaa actaactgt tgctatag g gcc ggt
Ala Gly
1524

atc cat gcc aag gct att ttc aag aac ccc tca aca tat gag att att
Ile His Ala Lys Ala Ile Leu Lys Asn Pro Ser Thr Tyr Glu Ile Ile
350 355 360 365

gttgttttgcgtatgtgca cgcacctgtx cgcacatggct atgtgagcc gaaatctca
1632

accacatt gatcg gac ccq act ctg ttc ggc atc act cgc tat gtc cac
Asp Pro Thr Leu Phe Gly Ile Thr Arg Tyr Val His
370 375

ttc gcc agc aga ttg aag gga tgg aac gca atc aag aag aca gca tgc
Phe Ala Ser Arg Leu Thr Gly Trp Asn Ala Ile Lys Ser Arg Ala Ser
1732
<210> 6
<211> 449
<212> PRT
<213> Magnaporthe grisea

<400> 6

Met Cys Pro Ser Cys Glu Pro Glu Gln Ala Ala Ala Ala Ser Asn Gly Asn 1 5 10 15
Ala Asn Gly Asn Gly Ala Ser Asn Gly Asn Gly Asn His Asp Gly Met 20 25 30
Thr Gly Ile Glu Thr Arg Gln Ala Gln Asn Ala Arg Tyr Gln Pro Ser
 35
 40
 45

Arg Asn Pro Tyr Gln Pro Val Gly Asp Phe Leu Ser Asn Val Asn Asn
 50
 55
 60

Phe Lys Ile Ile Glu Ser Thr Leu Arg Glu Gly Glu Gln Phe Ala Asn
 65
 70
 75
 80

Ala Phe Phe Asp Thr Ala Lys Lys Ile Glu Ile Ala Lys Ala Leu Asp
 85
 90
 95

Asp Phe Gly Val Asp Tyr Ile Glu Leu Thr Ser Pro Ala Ala Ala Ser Glu
100
105
110

Gln Ser Arg Leu Asp Cys Ala Ala Ile Cys Lys Leu Gly Leu Lys Ala
115
120
125

Lys Ile Leu Thr His Ile Arg Cys His Met Asp Asp Ala Arg Ile Ala
130
135
140

Val Glu Thr Gly Val Asp Gly Val Asp Ile Val Ile Gly Thr Ser Ser
145
150
155
160

Phe Leu Met Glu His Ser His Gly Lys Asp Met Thr Tyr Ile Thr Asn
165
170
175

Thr Ala Ile Glu Val Ile Asn Phe Val Lys Ser Lys Gly Ile Glu Val
180
185
190

Arg Phe Ser Ser Glu Asp Ser Phe Arg Ser Asn Leu Val Asp Leu Leu
195
200
205

Ser Ile Tyr Ser Thr Val Asp Lys Ile Gly Val Asn Arg Val Gly Ile
210
215
220

Ala Asp Thr Val Gly Cys Ala Ser Pro Arg Gln Val Tyr Asp Leu Val
225
230
235
240

Lys Thr Leu Arg Gly Val Val Ser Cys Asp Ile Glu Thr His Phe His
245
250
255

20
Asn Asp Thr Gly Cys Ala Ile Ser Asn Ala Phe Cys Ala Leu Glu Ala
260 265 270

Gly Ala Thr His Ile Asp Thr Cys Val Leu Gly Ile Gly Glu Arg Asn
275 280 285

Gly Ile Thr Pro Leu Gly Leu Met Ala Arg Met Ile Val Gly Ser
290 295 300

Lys Asp Tyr Val Leu Ser Lys Tyr Lys Leu His Lys Leu Lys Asp Ile
305 310 315 320

Glu Glu Leu Val Ala Asp Ala Val Gln Val Asn Ile Pro Phe Asn Asn
325 330 335

Tyr Ile Thr Gly Phe Cys Ala Phe Thr His Lys Ala Gly Ile His Ala
340 345 350

Lys Ala Ile Leu Lys Asn Pro Ser Thr Tyr Glu Ile Ile Asp Pro Thr
355 360 365

Leu Phe Gly Ile Thr Arg Tyr Val His Phe Ala Ser Arg Leu Thr Gly
370 375 380

Trp Asn Ala Ile Lys Ser Arg Ala Ser Gln Leu Asn Ile Glu Met Thr
385 390 395 400

Asp Glu Gln Cys Lys Glu Cys Thr Ala Lys Ile Lys Leu Leu Ala Asp
405 410 415

Ile Arg Pro Ile Ala Ile Asp Asp Ala Asp Ser Ile Ile His Ala Phe
420 425 430

His Arg Ser Ile Asn Ser Gly Gln Pro Ile Gln Ser Leu Gly Ser Leu
435 440 445

Leu
CLAIMS

What is claimed is:

1. A method for identifying a test compound as a candidate for an antibiotic, comprising:
   a) contacting an \( \alpha \)-Aminoacidic Reductase polypeptide with said test compound; and
   b) detecting the presence or absence of binding between said test compound and said \( \alpha \)-Aminoacidic Reductase polypeptide;

   wherein binding indicates that said test compound is a candidate for an antibiotic.

2. The method of claim 1, wherein said \( \alpha \)-Aminoacidic Reductase polypeptide is a fungal \( \alpha \)-Aminoacidic Reductase polypeptide.

3. The method of claim 1, wherein said \( \alpha \)-Aminoacidic Reductase polypeptide is a \textit{Magnaporthe} \( \alpha \)-Aminoacidic Reductase polypeptide.

4. The method of claim 1, wherein said \( \alpha \)-Aminoacidic Reductase polypeptide is

   SEQ ID NO: 3.

5. A method for determining whether a compound identified as an antibiotic candidate by the method of claim 1 has antifungal activity, further comprising:

   contacting a fungus or fungal cells with said antibiotic candidate and detecting the decrease in growth, viability, or pathogenicity of said fungus or fungal cells.
6. A method for identifying a test compound as a candidate for an antibiotic, comprising:

a) contacting said test compound with at least one polypeptide selected from the group consisting of: a polypeptide having at least ten consecutive amino acids of a fungal $\alpha$-Aminoadipate Reductase, a polypeptide having at least 50% sequence identity with a fungal $\alpha$-Aminoadipate Reductase, and a polypeptide having at least 10% of the activity thereof; and

b) detecting the presence and/or absence of binding between said test compound and said polypeptide;

wherein binding indicates that said test compound is a candidate for an antibiotic.

7. A method for determining whether a compound identified as an antibiotic candidate by the method of claim 6 has antifungal activity, further comprising:

contacting a fungus or fungal cells with said antibiotic candidate and detecting a decrease in growth, viability, or pathogenicity of said fungus or fungal cells.

8. A method for identifying a test compound as a candidate for an antibiotic, comprising:

a) contacting L-2-Aminoadipate and NADPH and ATP with an $\alpha$-Aminoadipate Reductase;

b) contacting L-2-Aminoadipate and NADPH and ATP with $\alpha$-Aminoadipate Reductase and said test compound; and

c) determining the change in concentration for at least one of the following: L-2-Aminoadipate, L-2-Aminoadipate 6-semialdehyde, NADP$^+$, NADPH, AMP, ATP, H$_2$O and/or pyrophosphate;
wherein a change in concentration for any of the above substances between steps (a) and (b) indicates that said test compound is a candidate for an antibiotic.

9. The method of claim 8, wherein said α-Aminoadipate Reductase is a fungal α-Aminoadipate Reductase.

10. The method of claim 8, wherein said α-Aminoadipate Reductase is a Magnaporthe α-Aminoadipate Reductase.

11. The method of claim 8, wherein said α-Aminoadipate Reductase is SEQ ID NO: 3.

12. A method for determining whether a compound identified as an antibiotic candidate by the method of claim 8 has antifungal activity, further comprising: contacting a fungus or fungal cells with said antibiotic candidate and detecting a decrease in growth, viability, or pathogenicity of said fungus or fungal cells.

13. A method for identifying a test compound as a candidate for an antibiotic, comprising:

a) contacting L-2-Aminoadipate 6-semialdehyde, NADP+, AMP, pyrophosphate, and H₂O with an α-Aminoadipate Reductase;

b) contacting L-2-Aminoadipate 6-semialdehyde, NADP+, AMP, pyrophosphate, and H₂O with an α-Aminoadipate Reductase and said test compound; and
c) determining the change in concentration for at least one of the following: L-2-
Aminoadipate, L-2-Aminoadipate 6-semialdehyde, NADP+, NADPH, AMP,
ATP, H₂O and/or pyrophosphate;

wherein a change in concentration for any of the above substances between steps (a)
and (b) indicates that said test compound is a candidate for an antibiotic.

14. The method of claim 13, wherein said α-Aminoadipate Reductase is a fungal α-
Aminoadipate Reductase.

15. The method of claim 13, wherein said α-Aminoadipate Reductase is a
Magnaporthe α-Aminoadipate Reductase.

16. The method of claim 13, wherein said α-Aminoadipate Reductase is SEQ ID NO:

17. A method for determining whether a compound identified as an antibiotic
candidate by the method of claim 13 has antifungal activity, further comprising:
contacting a fungus or fungal cells with said antibiotic candidate and detecting a
decrease in growth, viability, or pathogenicity of said fungus or fungal cells.

18. A method for identifying a test compound as a candidate for an antibiotic,
comprising:

a) contacting L-2-Aminoadipate and NADPH and ATP with a polypeptide selected
from the group consisting of: a polypeptide having at least 50% sequence
identity with an α-Aminoadipate Reductase, a polypeptide having at least 50%
sequence identity with an $\alpha$-Aminoadipate Reductase and having at least 10% of the activity thereof, and a polypeptide comprising at least 100 consecutive amino acids of an $\alpha$-Aminoadipate Reductase

b) contacting L-2-Aminoadipate and NADPH and ATP with said polypeptide and said test compound; and

c) determining the change in concentration for at least one of the following: L-2-Aminoadipate, L-2-Aminoadipate 6-semialdehyde, NADP+, NADPH, AMP, ATP, H$_2$O and/or pyrophosphate;

wherein a change in concentration for any of the above substances between steps (a) and (b) indicates that said test compound is a candidate for an antibiotic.

19. A method for identifying a test compound as a candidate for an antibiotic, comprising:

a) contacting L-2-Aminoadipate 6-semialdehyde, NADP+, AMP, pyrophosphate, and H$_2$O with a polypeptide selected from the group consisting of: a polypeptide having at least 50% sequence identity with an $\alpha$-Aminoadipate Reductase, a polypeptide having at least 50% sequence identity with an $\alpha$-Aminoadipate Reductase and at least 10% of the activity thereof, and a polypeptide comprising at least 100 consecutive amino acids of an $\alpha$-Aminoadipate Reductase

b) contacting L-2-Aminoadipate 6-semialdehyde, NADP+, AMP, pyrophosphate, and H$_2$O, with said polypeptide and said test compound; and

c) determining the change in concentration for at least one of the following: L-2-Aminoadipate, L-2-Aminoadipate 6-semialdehyde, NADP+, NADPH, AMP, ATP, H$_2$O and/or pyrophosphate;
wherein a change in concentration for any of the above substances between steps (a) and (b) indicates that said test compound is a candidate for an antibiotic.

20. A method for identifying a test compound as a candidate for an antibiotic, comprising:

a) measuring the expression of an \( \alpha \)-Aminoadipate Reductase in a cell, cells, tissue, or an organism in the absence of said compound;

b) contacting said cell, cells, tissue, or organism with said test compound and measuring the expression of said \( \alpha \)-Aminoadipate Reductase in said fungus or fungal cell;

c) comparing the expression of \( \alpha \)-Aminoadipate Reductase in steps (a) and (b); wherein a lower expression in the presence of said test compound indicates that said compound is a candidate for an antibiotic.

21. The method of claim 20 wherein said cell, cells, tissue, or organism is, or is derived from a fungus.

22. The method of claim 20 wherein said cell, cells, tissue, or organism is, or is derived from a *Magnaporthe* fungus or fungal cell.

23. The method of claim 20, wherein said \( \alpha \)-Aminoadipate Reductase is SEQ ID NO: 3.

24. The method of claim 20, wherein the expression of \( \alpha \)-Aminoadipate Reductase is measured by detecting AAR1 mRNA.
25. The method of claim 20, wherein the expression of α-Aminoacidipate Reductase is measured by detecting α-Aminoacidipate Reductase polypeptide.

26. A method for identifying a test compound as a candidate for an antibiotic, comprising:
   a) providing cells having one form of an α-Aminoacidipate Reductase gene, and providing comparison cells having a different form of an α-Aminoacidipate Reductase gene,
   b) contacting said cells and said comparison cells with a test compound and determining the growth of said cells and comparison cells in the presence of the test compound;
   wherein a difference in growth between said cells and said comparison cells in the presence of said compound indicates that said compound is a candidate for an antibiotic.

27. The method of claim 26 wherein the cells are fungal cells.

28. The method of claim 26 wherein the cells are *Magnaporthe* cells.

29. The method of claim 26 wherein said form and said comparison form of the α-Aminoacidipate Reductase are fungal α-Aminoacidipate Reductases.

30. The method of claim 26, wherein at least one form is a *Magnaporthe* α-Aminoacidipate Reductase.
31. The method of claim 26 wherein said form and said comparison form of the α-
Amino adipate Reductase are non-fungal α-Amino adipate Reductases.

32. The method of claim 26 wherein one form of the α-Amino adipate Reductase is a
fungal α-Amino adipate Reductase, and the other form is a non-fungal α-
Amino adipate Reductase.

33. A method for identifying a test compound as a candidate for an antibiotic,
comprising:

a) providing cells having one form of a gene in the lysine biochemical and/or genetic
pathway and providing comparison cells having a different form of said gene.

b) contacting said cells and comparison cells with a said test compound,

c) determining the growth of said cells and comparison cells in the presence of said
test compound;

wherein a difference in growth between said cells and said comparison cells in the
presence of said compound indicates that said compound is a candidate for an
antibiotic.

34. The method of claim 33 wherein the cells are fungal cells.

35. The method of claim 33 wherein the cells are Magnaporthe cells.

36. The method of claim 33 wherein said form and said comparison form of the lysine
biosynthesis gene are fungal lysine biosynthesis genes.
37. The method of claim 33, wherein at least one form is a *Magnaporthe* lysine biosynthesis gene.

38. The method of claim 33 wherein said form and said comparison form of the lysine biosynthesis genes are non-fungal lysine biosynthesis genes.

39. The method of claim 33 wherein one form of the lysine biosynthesis gene is a fungal lysine biosynthesis gene, and the other form is a non-fungal lysine biosynthesis gene.

40. A method for determining whether a test compound identified as an antibiotic candidate by the method of claim 33 has antifungal activity, further comprising: contacting a fungus or fungal cells with said antibiotic candidate and detecting a decrease in growth, viability, or pathogenicity of said fungus or fungal cells.

41. A method for identifying a test compound as a candidate for an antibiotic, comprising:
   (a) providing paired growth media; comprising a first medium and a second medium, wherein said second medium contains a higher level of lysine than said first medium;
   (b) contacting an organism with said test compound;
   (c) inoculating said first and second media with said organism; and
   (d) determining the growth of said organism;
wherein a difference in growth of the organism between said first and second media indicates that said test compound is a candidate for an antibiotic.

42. The method of claim 41, wherein said organism is a fungus.

43. The method of claim 41, wherein said organism is *Magnaporthe*.

44. An isolated polynucleotide comprising a nucleotide sequence that encodes a polypeptide of SEQ ID NO: 3.

45. The polynucleotide of claim 44 comprising the nucleotide sequence of SEQ ID NO: 1.

46. An expression cassette comprising the polynucleotide of claim 45.

47. The isolated polynucleotide of claim 44 comprising a nucleotide sequence of at least 50 to at least 95% sequence identity to SEQ ID NO: 1.

48. A polypeptide consisting essentially of the amino acid sequence of SEQ ID NO: 3.

49. A polypeptide comprising the amino acid sequence of SEQ ID NO: 3.

50. A method for identifying a test compound as a candidate for an antibiotic, comprising:

   a) contacting a homocitrate synthase polypeptide with said test compound; and
b) detecting the presence or absence of binding between said test compound and said homocitrate synthase polypeptide;

wherein binding indicates that said test compound is a candidate for an antibiotic.

51. The method of claim 50, wherein said homocitrate synthase polypeptide is a fungal homocitrate synthase polypeptide.

52. The method of claim 50, wherein said homocitrate synthase polypeptide is a Magnaporthe homocitrate synthase polypeptide.

53. The method of claim 50, wherein said homocitrate synthase polypeptide is SEQ ID NO: 6.

54. A method for determining whether a compound identified as an antibiotic candidate by the method of claim 50 has antifungal activity, further comprising: contacting a fungus or fungal cells with said antibiotic candidate and detecting the decrease in growth, viability, or pathogenicity of said fungus or fungal cells.

55. A method for identifying a test compound as a candidate for an antibiotic, comprising:

a) contacting said test compound with at least one polypeptide selected from the group consisting of: a polypeptide having at least ten consecutive amino acids of a fungal homocitrate synthase, a polypeptide having at least 50% sequence identity with a fungal homocitrate synthase, and a polypeptide having at least 10% of the activity thereof; and
56. A method for determining whether a compound identified as an antibiotic candidate by the method of claim 55 has antifungal activity, further comprising:
  contacting a fungus or fungal cells with said antibiotic candidate and detecting a decrease in growth, viability, or pathogenicity of said fungus or fungal cells.

57. A method for identifying a test compound as a candidate for an antibiotic, comprising:
  a) contacting acetyl-CoA and H$_2$O and 2-oxoglutarate with a homocitrate synthase;
  b) contacting acetyl-CoA and H$_2$O and 2-oxoglutarate with a homocitrate synthase and said test compound; and
  c) determining the change in concentration for at least one of the following: 2-hydroxybutane-1,2,4-tricarboxylate, 2-oxoglutarate, acetyl-CoA, CoA, and/or H$_2$O;
  wherein a change in concentration for any of the above substances between steps (a) and (b) indicates that said test compound is a candidate for an antibiotic.

58. The method of claim 57, wherein said homocitrate synthase is a fungal homocitrate synthase.

59. The method of claim 57, wherein said homocitrate synthase is a Magnaporthe homocitrate synthase.
60. The method of claim 57, wherein said homocitrinate synthase is SEQ ID NO: 6.

61. A method for determining whether a compound identified as an antibiotic candidate by the method of claim 57 has antifungal activity, further comprising: contacting a fungus or fungal cells with said antibiotic candidate and detecting a decrease in growth, viability, or pathogenicity of said fungus or fungal cells.

62. A method for identifying a test compound as a candidate for an antibiotic, comprising:
   a) contacting 2-hydroxybutane-1,2,4-tricarboxylate and CoA with a homocitrinate synthase;
   b) contacting 2-hydroxybutane-1,2,4-tricarboxylate and CoA with a homocitrinate synthase and said test compound; and
   c) determining the change in concentration for at least one of the following: 2-hydroxybutane-1,2,4-tricarboxylate, 2-oxoglutarate, acetyl-CoA, CoA, and/or H₂O;

wherein a change in concentration for any of the above substances between steps (a) and (b) indicates that said test compound is a candidate for an antibiotic.

63. The method of claim 62, wherein said homocitrinate synthase is a fungal homocitrinate synthase.

64. The method of claim 62, wherein said homocitrinate synthase is a Magnaporthe homocitrinate synthase.
65. The method of claim 62, wherein said homocitrate synthase is SEQ ID NO: 6.

66. A method for determining whether a compound identified as an antibiotic candidate by the method of claim 62 has antifungal activity, further comprising: contacting a fungus or fungal cells with said antibiotic candidate and detecting a decrease in growth, viability, or pathogenicity of said fungus or fungal cells.

67. A method for identifying a test compound as a candidate for an antibiotic, comprising:

a) contacting acetyl-CoA and H₂O and 2-oxoglutarate with a polypeptide selected from the group consisting of: a polypeptide having at least 50% sequence identity with a homocitrate synthase, a polypeptide having at least 50% sequence identity with a homocitrate synthase and having at least 10% of the activity thereof, and a polypeptide comprising at least 100 consecutive amino acids of a homocitrate synthase;

b) contacting acetyl-CoA and H₂O and 2-oxoglutarate with said polypeptide and said test compound; and

c) determining the change in concentration for at least one of the following: 2-hydroxybutane-1,2,4-tricarboxylate, 2-oxoglutarate, acetyl-CoA, CoA, and/or H₂O;

wherein a change in concentration for any of the above substances between steps (a) and (b) indicates that said test compound is a candidate for an antibiotic.
68. A method for identifying a test compound as a candidate for an antibiotic, comprising:

a) contacting 2-hydroxybutane-1,2,4-tricarboxylate and CoA with a polypeptide selected from the group consisting of: a polypeptide having at least 50% sequence identity with a homocitrate synthase, a polypeptide having at least 50% sequence identity with a homocitrate synthase and at least 10% of the activity thereof, and a polypeptide comprising at least 100 consecutive amino acids of a homocitrate synthase;

b) contacting 2-hydroxybutane-1,2,4-tricarboxylate and CoA, with said polypeptide and said test compound; and

c) determining the change in concentration for at least one of the following: 2-hydroxybutane-1,2,4-tricarboxylate, 2-oxoglutarate, acetyl-CoA, CoA, and/or H₂O;

wherein a change in concentration for any of the above substances between steps (a) and (b) indicates that said test compound is a candidate for an antibiotic.

69. A method for identifying a test compound as a candidate for an antibiotic, comprising:

a) measuring the expression of a homocitrate synthase in a cell, cells, tissue, or an organism in the absence of said compound;

b) contacting said cell, cells, tissue, or organism with said test compound and measuring the expression of said homocitrate synthase in said fungus or fungal cell;

c) comparing the expression of homocitrate synthase in steps (a) and (b);
wherein a lower expression in the presence of said test compound indicates that said compound is a candidate for an antibiotic.

70. The method of claim 69 wherein said a cell, cells, tissue, or organism is, or is derived from a fungus.

71. The method of claim 69 wherein said cell, cells, tissue, or organism is, or is derived from a Magnaporthe fungus or fungal cell.

72. The method of claim 69, wherein said homocitrate synthase is SEQ ID NO: 3.

73. The method of claim 69, wherein the expression of homocitrate synthase is measured by detecting HCS1 mRNA.

74. The method of claim 69, wherein the expression of homocitrate synthase is measured by detecting homocitrate synthase polypeptide.

75. A method for identifying a test compound as a candidate for an antibiotic, comprising:
   a) providing cells having one form of a homocitrate synthase gene, and providing comparison cells having a different form of a homocitrate synthase gene,
   b) contacting said cells and said comparison cells with a test compound and determining the growth of said cells and comparison cells in the presence of the test compound; wherein a difference in growth between said cells and said
comparison cells in the presence of said compound indicates that said compound is a candidate for an antibiotic.

76. The method of claim 75 wherein the cells are fungal cells.

77. The method of claim 75 wherein the cells are *Magnaporthe* cells.

78. The method of claim 75 wherein said form and said comparison form of the homocitrate synthase are fungal homocitrate synthases.

79. The method of claim 75, wherein at least one form is a *Magnaporthe* homocitrate synthase.

80. The method of claim 75 wherein said form and said comparison form of the homocitrate synthase are non-fungal homocitrate synthases.

81. The method of claim 75 wherein one form of the homocitrate synthase is a fungal homocitrate synthase, and the other form is a non-fungal homocitrate synthase.

82. A method for identifying a test compound as a candidate for an antibiotic, comprising:

a) providing cells having one form of a gene in the lysine biochemical and/or genetic pathway and providing comparison cells having a different form of said gene.
b) contacting said cells and comparison cells with a said test compound,

c) determining the growth of said cells and comparison cells in the presence of said test compound; wherein a difference in growth between said cells and said comparison cells in the presence of said compound indicates that said compound is a candidate for an antibiotic.

83. The method of claim 82 wherein the cells are fungal cells.

84. The method of claim 82 wherein the cells are Magnaporthe cells.

85. The method of claim 82 wherein said form and said comparison form of the lysine biosynthesis gene are fungal lysine biosynthesis genes.

86. The method of claim 82, wherein at least one form is a Magnaporthe lysine biosynthesis gene.

87. The method of claim 82 wherein said form and said comparison form of the lysine biosynthesis genes are non-fungal lysine biosynthesis genes.

88. The method of claim 82 wherein one form of the lysine biosynthesis gene is a fungal lysine biosynthesis gene, and the other form is a non-fungal lysine biosynthesis gene.
89. A method for determining whether a test compound identified as an antibiotic candidate by the method of claim 82 has antifungal activity, further comprising: contacting a fungus or fungal cells with said antibiotic candidate and detecting a decrease in growth, viability, or pathogenicity of said fungus or fungal cells.

90. A method for identifying a test compound as a candidate for an antibiotic, comprising:

(a) providing paired growth media; comprising a first medium and a second medium, wherein said second medium contains a higher level of lysine than said first medium;

(b) contacting an organism with said test compound;

(c) inoculating said first and second media with said organism; and

(d) determining the growth of said organism;

wherein a difference in growth of the organism between said first and second media indicates that said test compound is a candidate for an antibiotic.

91. The method of claim 90, wherein said organism is a fungus.

92. The method of claim 90, wherein said organism is Magnaporthe.

93. An isolated polynucleotide comprising a nucleotide sequence that encodes a polypeptide of SEQ ID NO: 6.

94. The polynucleotide of claim 93 comprising the nucleotide sequence of SEQ ID NO: 4.
95. An expression cassette comprising the polynucleotide of claim 94.

96. The isolated polynucleotide of claim 93 comprising a nucleotide sequence of at least 50 to at least 95% sequence identity to SEQ ID NO: 4.

97. A polypeptide consisting essentially of the amino acid sequence of SEQ ID NO: 6.

98. A polypeptide comprising the amino acid sequence of SEQ ID NO: 6.
Figure 1

\[
\begin{align*}
L-2\text{-Aminoadipate} + NADPH + ATP & \quad \downarrow \quad \alpha\text{-Aminoadipate Reductase} + Mg^{2+} \\
L-2\text{-Aminoadipate 6-semialdehyde} + NADP^{+} + AMP + pyrophosphate + H_{2}O & \quad \uparrow
\end{align*}
\]
Figure 2

Negative Control
Guy11
KO1-1
KO1-11
Figure 3

A.

```
<table>
<thead>
<tr>
<th>Time (days)</th>
<th>Turbidity (490nm + 750nm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.2</td>
</tr>
<tr>
<td>2</td>
<td>0.4</td>
</tr>
<tr>
<td>3</td>
<td>0.6</td>
</tr>
<tr>
<td>4</td>
<td>0.8</td>
</tr>
<tr>
<td>5</td>
<td>1.0</td>
</tr>
<tr>
<td>6</td>
<td>1.2</td>
</tr>
<tr>
<td>7</td>
<td>1.4</td>
</tr>
</tbody>
</table>
```

B.

```
<table>
<thead>
<tr>
<th>Time (days)</th>
<th>Turbidity (490nm + 750nm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.2</td>
</tr>
<tr>
<td>2</td>
<td>0.4</td>
</tr>
<tr>
<td>3</td>
<td>0.6</td>
</tr>
<tr>
<td>4</td>
<td>0.8</td>
</tr>
<tr>
<td>5</td>
<td>1.0</td>
</tr>
<tr>
<td>6</td>
<td>1.2</td>
</tr>
<tr>
<td>7</td>
<td>1.4</td>
</tr>
</tbody>
</table>
```
Figure 4

Acetyl CoA + H₂O + 2-oxoglutarate

\[ \text{Homocitrate synthase} \]

\[ \text{2-hydroxybutane-1,2,4-tricarboxylate + CoA} \]
Figure 5

Negative Control
Wild-type
KO1-1
KO1-2
Figure 6

A.

B.